CLINICAL STUDY PROTOCOL 
Protocol Title:  A Multi-Center, Randomized, Double-Blind, Dose-Ranging, 
Placebo-Controlled, Proof of Concep t, Adaptive, Phase 1b Clinical 
Study to Evaluate the Safety, Phar macokinetics, Ph armacodynamics, 
and Efficacy of Orally Adminis tered TERN-201 in Patients with 
Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) 
Protocol Number: TERN201-1007 
Protocol Version:  Amendment 3 
Version Date:  [ADDRESS_524706] 2021 
Supersedes: Amendment 2; 21 June 2021 
Compound:  TERN-201 
Study Phase:  1b 
Sponsor Name:  [CONTACT_416490].  
Legal Registered 
Address:  [ADDRESS_524707]. Suite 100 Foster City, [LOCATION_004] [ZIP_CODE] 
Regulatory Agency Identifier Number(s) 
US FDA IND:   
CONFIDENTIAL 
This document contains confiden tial information, which should not be copi[INVESTIGATOR_530], referred to, 
released, or published without written approval from Terns, Inc. 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524708] 2021 
CONFIDENTIAL  Page 2 of 92  Sponsor Signatory:
 
President and Chief Medical Officer
Terns, Inc. Date 
 
  

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524709] 2021 
 
CONFIDENTIAL  Page 3 of 92  Table of Contents 
1. Protocol Summary ..........................................................................................................6  
1.1. Synopsis ...................................................................................................................... ......6  
1.2. Schema ........................................................................................................................ ....11  
1.3. Schedule of Activities .....................................................................................................12  
2. Introduction .................................................................................................................. .19 
2.1. Overview of NASH and Role of VAP-1/SSAO in Disease............................................19  
2.2. VAP-1/SSAO Inhibition in NAS H and TERN-201 Background ...................................20  
2.2.1.  Summary of Nonclinical Studies ....................................................................................21  
2.2.2.  Clinical Studies of TERN-201 ........................................................................................24  
2.3. Benefit/Risk Assessment ................................................................................................25  
3. Objectives and Endpoin ts ............................................................................................27  
4. Study Design ..................................................................................................................29  
4.1. Overall Design ................................................................................................................ 29 
4.2. Scientific Ra tionale for Study Design ............................................................................30  
4.3. Justification for Dose ......................................................................................................31  
5. Study Population ...........................................................................................................32  
5.1. Inclusion Criteria ............................................................................................................32  
5.2. Exclusion Criteria ...........................................................................................................3 3 
5.3. Lifestyle Considerations .................................................................................................37  
5.3.1.  Lifestyle Counseling .......................................................................................................37  
5.3.2.  Meals and Dietary Restrictions .......................................................................................37  
5.3.3.  Alcohol, Cannabis, a nd Illicit Drug Use .........................................................................37  
5.4. Screen Failures ............................................................................................................... .38 
6. Study Drug..................................................................................................................... 39 
6.1. Study Drug(s) Administered ...........................................................................................39  
6.2. Study Drug Administration .............................................................................................39  
6.3. Preparation/Handling/Storage/Accountability ................................................................40  
6.4. Measures to Minimize Bias: Randomization and Blinding ............................................40  
6.4.1.  Unblinding .................................................................................................................... ..41 
6.4.2.  Patient Enrollment and Study Drug Assignment ............................................................42  
6.5. Study Drug Compliance..................................................................................................42  
6.6. Concomitant Therapy .....................................................................................................42  
6.7. Dose Modifications .........................................................................................................43  
6.8. Dose Interruptions...........................................................................................................44  
6.8.1.  Dose Interruptions due to COVID-19 .............................................................................44  
6.9. Intervention after the End of the Study ...........................................................................44  
7. Discontinuation of Study Drug and Patient 
Discontinuation/Withdrawal........................................................................................45  
7.1. Discontinuation of Study Drug .......................................................................................45  
7.2. Patient Discontinua tion/Withdrawal from the Study ......................................................[ADDRESS_524710] to Follow up ............................................................................................................46  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524711] 2021 
 
CONFIDENTIAL  Page 4 of 92  8. Study Assessments and Procedures.............................................................................47  
8.1. Study Assessments ..........................................................................................................47  
8.1.1.  Demographics .................................................................................................................4 7 
8.1.2.  Height and Weight ..........................................................................................................47  
8.1.3.  Medical History ..............................................................................................................48  
8.1.4.  Physical Examinations ....................................................................................................48  
8.1.5.  Vital Signs ................................................................................................................... ....48  
8.1.6.  Electrocardiograms .........................................................................................................48  
8.1.7.  Clinical Laboratory Assessments ....................................................................................49  
8.1.8.  Transient Elastography and Controlled Attenuation Parameter .....................................49  
8.1.9.  Magnetic Resonance Imaging: Co rrect T1 and Proton Density 
Fat Fraction .....................................................................................................................50  
8.2. Pharmacokinetics ............................................................................................................51  
8.3. Pharmacodynamics .........................................................................................................52  
8.4. Biomarkers .................................................................................................................... ..52 
8.5. Adverse Events and Seri ous Adverse Events .................................................................53  
8.5.1.  Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................................................... ..53 
8.5.2.  Method of Detecti ng AEs and SAEs ..............................................................................54  
8.5.3.  Follow-up of AEs and SAEs ...........................................................................................54  
8.5.4.  Regulatory Reporting Requirements for SAEs ...............................................................54  
8.5.5.  Pregnancy ..................................................................................................................... ...55  
8.6. Treatment of  Overdose ...................................................................................................55  
9. Statistical Considerations .............................................................................................56  
9.1. Statistical Hypotheses .....................................................................................................56  
9.2. Sample Size Determination ............................................................................................56  
9.3. Analysis Sets ...................................................................................................................56  
9.4. Statistical Analyses .........................................................................................................57  
9.4.1.  General Considerations ...................................................................................................57  
9.4.2.  Primary Endpoint(s) ........................................................................................................57  
9.4.3.  Secondary Endpoints ......................................................................................................57  
9.4.4.  Exploratory Endpoints ....................................................................................................58  
9.5. Interim Analysis .............................................................................................................. 59 
10. Regulatory, Ethical, and Study Oversight Considerations .......................................61  
10.1.  Regulatory and Ethical Considerations...........................................................................61  
10.1.1.  Financial Disclosure........................................................................................................61  
10.1.2.  Informed Consent Process ..............................................................................................62  
10.1.3.  Data Protection................................................................................................................ 62 
10.1.4.  Dissemination of Clinical Study Data.............................................................................63  
10.1.5.  Data Quality Assurance ..................................................................................................63  
10.1.6.  Protocol Deviations .........................................................................................................64  
10.1.7.  Source Documents ..........................................................................................................64  
10.1.8.  Study and Site Start and Closure ....................................................................................65  
Appendix 1: Clinical Laboratory Tests ......................................................................................... .67 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524712] 2021 
 
CONFIDENTIAL  Page 5 of 92  Appendix 2: Sample Collecti on for Pharmacokinetics and 
Pharmacodynamics .........................................................................................................70  
Appendix 3: Liver Chemistry In creased Monitoring Criteria ........................................................72  
Appendix 4: Fridericiaâ€™s Formula ..................................................................................................73  
Appendix 5: Chronic Kidney Diseas e Epi[INVESTIGATOR_10444] (CKD-
EPI) Formula to Estimate Gl omerular Filtration Rate ....................................................74  
Appendix 6: Adverse Events: Definiti ons and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ............................................................................75  
Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................... ..80 
Appendix 8: COVID-19 Assessments ...........................................................................................84  
Appendix 9: Abbreviations ............................................................................................................85  
Appendix 10: Investigat or Signature [CONTACT_3490] ....................................................................................89  
Appendix 11: Protocol Amendment History .................................................................................90  
Appendix 12: Re ferences ....................................................................................................... ........[ADDRESS_524713] of Tables 
Table 1  Study Drug by [CONTACT_61116] ............................................................................... 40  
Table 2  Protocol-Required Clinical Laboratory Assessments ....................................... 67  
Table 3  PK/PD Sampling Timepoints ............................................................................ [ADDRESS_524714] of Figures 
Figure 1 Efficacy of TERN-201 in a CDHFD+NaNO 2 Rat Model of NASH .............................. 22  
 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524715] 2021 
 
CONFIDENTIAL  Page 6 of 92  1. Protocol Summary 
1.1. Synopsis 
Protocol Title:  
A Multi-Center, Randomized, D ouble-Blind, Dose-Ranging, Pl acebo-Controlled, Proof of 
Concept, Adaptive, Phase 1b Clinical Study to  Evaluate the Safety, Pharmacokinetics, 
Pharmacodynamics, and Pr eliminary Efficacy of Orally Administered TERN- 201 in Patients 
with Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524716] 2021 
 
CONFIDENTIAL  Page 7 of 92  Objectives:  
Primary Objective:  
x To characterize the safety and tolerability of TERN-201 versus placebo for 12 weeks in 
non-cirrhotic presumed NASH patients, with clinical or histological NASH diagnosis 
Secondary Objectives: 
x To assess the plasma and urine PK of TERN -[ADDRESS_524717] of TERN-201 vers us placebo for 12 weeks on plasma VAP-
1/SSAO activity in non-cirrhotic  presumed NASH patients 
Exploratory Objectives: 
x To assess the plasma and urine PK of TERN-201 metabolites (including TRN-001021 
and TRN-001744) at steady state 
x To assess the effect of TERN-[ADDRESS_524718] of TERN-201 versus  placebo on biomarkers of inflammation 
x To explore the potential for TERN-201 to impr ove proteinuria due to  endothelial effects 
x To explore other PD markers, and ove rall exposure-response and dose-response 
relationship of TERN-201, as applicable 
x To explore the exposure-response and dose-re sponse relationship, as applicable, of 
TERN-201 and baseline patient characteristic s such as soluble VAP-1 (sVAP-1), body 
mass index (BMI), diabetes mellitus, and others 
Endpoints:  
Primary Endpoint:  
x Overall safety assessed by [CONTACT_416457] (TEAEs) and treatment emergent 
clinical safety labo ratory abnormalities  
Secondary Endpoints:  
x Plasma and urine PK pa rameters for TERN-201  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524719] 2021 
 
CONFIDENTIAL  Page 8 of 92  x Percent change from baseline in plasma VAP-1/SSAO activity 
Exploratory Endpoints:  
x Plasma and urine PK parameters for TERN-201 metabolites (i ncluding TRN-001021 and 
TRN-001744) 
x Change from baseline in corrected T1 (c T1) by [CONTACT_9252] (MRI) 
x Change from baseline in liver fat content by [CONTACT_9252]-proton density 
fat fraction (MRI-PDFF) 
x Change from baseline in stiffness by [CONTACT_331436]  
x Change from baseline in alanin e aminotransferase (ALT)  
x Change from baseline in gamma-glutamyl transpeptidase (GGT) 
x Change from baseline in aspart ate aminotransferase (AST) 
x Change from baseline in NASH and fibrosis biomarkers including cytokeratin-18 (CK-
18) (M30 and M65), procollagen III n-terminal propeptide (PI[INVESTIGATOR_120861]), tissue inhibitor of metalloproteinases-1 (TIMP-1), hyaluronic acid (HA), pro-peptide of type III collagen (PRO-C3), and type III collagen (C3M). Other non-invasive tests for NASH fibrosis may 
also be assessed including the fibrosis-4 (FIB-4 ) index, enhanced liver fibrosis (ELF) test, 
NAFLD fibrosis score (NFS), and PRO-C3/C3M ratio. 
x Change from baseline in inflammatory biom arkers including high sensitivity C-reactive 
protein (hs-CRP), interleukin-6 (IL-6), intercellular adhesion mole cule-1 (ICAM-1), and 
vascular cell adhesion molecule-1 (VCAM-1) 
x Change from baseline in estimated glomerular filtration rate (eGFR), urine protein including urine protein-to-creatinine ratio (U PCR), and urine albumin-to-creatinine ratio 
(UACR)  
x Change from baseline in plasma methylamine levels (PD marker of VAP-1/SSAO inhibition) 
x Exposure-response and dose-response rela tionship of TERN-201 over 12 weeks, as 
applicable  
x Exposure-response and dose-response relationship, as applicable, of TERN-201 and baseline patient characteristics such as sVAP-1, BMI, diabetes mellitus, and others 
Overall Design: 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524720] 2021 
 
CONFIDENTIAL  Page 9 of 92  The study is a multi-center, randomized, doubl e-blind, placebo-controlled, adaptive study. 
Approximately 80 clinically or histologically diagnosed adult non-cirrhotic presumed NASH 
patients who meet study eligibility criteria will be enrolled and ra ndomized at an overall ratio of 
2:1 into 3 dose groups and placebo across 2 parts of the study.  
Part 1  
In Part 1, approximately 30 pa tients will receive 10 mg TERN- 201 (n = 20) or matching placebo 
(n = 10) orally once daily, for [ADDRESS_524721] dose (Week 0/Day 1), at Week 6, and after the last dose of study 
drug (Week 12). Randomization will ensure a pproximately 8 patients in the TERN-201 group 
and approximately 4 pati ents in the placebo group are assi gned to the PK/PD sub-study. Patients 
who are not participating in the PK/PD s ub-study will have trough PK/PD sampling only. 
Part 2 may be enrolled based on an  interim analysis, as follows: 
An interim analysis will be performed after all patients in Part [ADDRESS_524722] completed Week 6 
assessments. Interim PK and PD data will be assessed. Blinded safety data will also be reviewed. Enrollment of cohorts to a ssess 4 mg and up to 20 mg TER N-201 may be initiated per the 
following criteria:  
x TERN-201 4 mg:  
o If robust VAP-1/SSAO activity suppression is  observed  and available PK from 
Part [ADDRESS_524723] VAP-1/SSAO 
activity suppression, enrollment in Part 2 with 4 mg TERN-201 may be initiated.  
x TERN-201 up to 20 mg: 
o If safety data indicates 10 mg TERN-201 is overall safe and well-tolerated, and 
available PK from Part 1 predicts that ta rgeted exposures for a dose up to 20 mg 
will be below an upper limit of 5400 ngâ€¢hr/mL for AUC
0-24hr and 768 ng/mL for 
Cmax, enrollment in Part 2 with a dose up to 20 mg TERN-201 may be initiated. 
Part 2  
In Part 2, if initiated, approxima tely 50 patients will receive 4 mg  TERN-201 (n = 20), and/or up 
to 20 mg TERN-201 (n = 20), or matching placeb o (n = 10) orally once daily, for 12 weeks. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524724] dose (Week 0/Day 1), at Week 6, and after the last dose of study 
drug (Week 12). Randomization will ensure a pproximately 6 patients at each TERN-201 dose 
level and approximately 3 patients in the placebo group are assigned to the PK/PD sub-study. 
Patients who are not participating in the PK/PD sub-study will have trough PK/PD sampling 
only. 
The total duration of study participation will be approximately 22 weeks, consisting of a 6-week 
Screening Period, a 12-week Treatment Period and a 4-week Follow-up Period.  
Number of Patients: 
Approximately 80 patient s will be randomly assigned to trea tment with TERN-201 capsule or 
matching placebo. 
Patients who are randomized but do not receive study drug for any reason may be replaced. In 
addition, patients who discon tinue treatment early for reasons ot her than safety (i.e., withdrawal 
of consent, lost to follow-up, pa tient relocated, etc.) may also be replaced. Replacement patients 
will receive the same treatment assignment as the patient that  discontinued treatment early. 
Study Centers Planned:  
Up to 15 centers in the [LOCATION_002]. 
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524725] 2021 
  
CONFIDENTIAL Page 11 of 92  1.2. Schema 
 

Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524726]-randomization 
through Week 12: Â± 3 days from the 
specified study day. Visit window 
Week 16: 1 week prior/+[ADDRESS_524727] dose of study 
drug.  
Demographics X         Includes age, sex, and race/ethnicity.  
Height and 
Weight X X X X X X X X X Height and weight are collected at Screening and will be used to calculate BMI for eligibility. Waist circumference is also measured at Screening. Only weight is collected on other days 
indicated.  
Medical History  X X        Includes details of illnesses and allergies, 
date(s) of onset, whether condition(s) is currently ongoing, and medication history, including alcohol use. 
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524728]-randomization 
through Week 12: Â± 3 days from the 
specified study day. Visit window Week 16: 1 week prior/+[ADDRESS_524729] stability may be evaluated prior to randomization per Section 5. 
Increased monitoring criteria for elevated 
ALT and/or AST above 2 Ã— Baseline or above 5 Ã— ULN for < 1 week is outlined 
in Appendix 3
. 
 
Refer to Appendix 5  for the eGFR 
formula, to be calculated by [CONTACT_35970].  
Hematologyd X X X X X X X X X Specific analytes are listed in Appendix 1.  
Coagulationd X X        Specific analytes are listed in Appendix 1. 
PT/INR will be tested at Screening, Week 0, and if significant abnormal liver 
function tests are observed. 
Fasting Lipid 
Profiled  X   X  X X  Specific analytes are listed in Appendix 1.  
Serology X         Includes HBsAg, anti-HCV, and anti-
HIV.  
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524730]-randomization 
through Week 12: Â± 3 days from the 
specified study day. Visit window Week 16: 1 week prior/+[ADDRESS_524731] X 
         
Urinalysisd X X   X  X X X Specific analytes are listed in Appendix 1. 
Microscopic examination is required if 
blood or protein is abnormal. 
Urine Drug Screen
d X X  X  X X X X  
Total Urine Collection (PK/PD Sub-Study only)   
X   X     Total urine collection from 0-[ADDRESS_524732] 
dose as specified in Appendix 2.  
Intensive PK and PD Sampling (PK/PD Sub-
Study only)  
X   X  X   Intensive PK sampling will be performed 
pre-dose and 0.5, 1, 2, 4, 6, [ADDRESS_524733] dose of study drug on Week 0/Day [ADDRESS_524734] dose of study drug 
at Week 12. Refer to Appendix 2 for 
additional detail.  
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524735]-randomization 
through Week 12: Â± 3 days from the 
specified study day. Visit window Week 16: 1 week prior/+[ADDRESS_524736] one 
sample collected at th e ET visit. Refer to 
Appendix 2 for additional detail. 
Baseline  sVAP-1f  X         
NASH/Fibrosis Biomarkers
d  X   X  X X  Includes CK-18 (M30 and M65), PI[INVESTIGATOR_120861], 
TIMP-1, HA, PRO-C3, and C3M. 
Inflammation Biomarkers
d  X X X X X X X  Includes hs-CRP, IL-6, ICAM-1, and 
VCAM-1. 
12-lead ECG X X   X  X   In addition to the scheduled timepoints, perform ad-hoc ECG in the instance of patient-reported symptoms considered potentially cardiac in nature such as chest pain/pressure, palpi[INVESTIGATOR_814], dizziness, shortness of breath, or report of patient 
recently seeking medical care for such 
symptoms (e.g., emergency room visit); obtain cardiology consult based on the 
clinical judgement of the Investigator. 
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524737]-randomization 
through Week 12: Â± 3 days from the 
specified study day. Visit window Week 16: 1 week prior/+2 days from the 
specified study day.
 
Transient 
Elastography X      X X  A historical transient elastography report within 3 months of Screening may be used to determine eligibility for this study. See inclusion/exclusion criteria for 
details.  
MRI cT1g X    X  X X  A Screening MRI cT1 may proceed on 
the basis of the initial ALT and AST levels at Screening, given all other eligibility criteria are met, but randomization should not occur prior to confirmation of ALT and AST stability, 
as necessary.  
 
An MRI cT1 should be performed at ET if the patient has had at least [ADDRESS_524738] of care management for a NASH patient 
population.  
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524739]-randomization 
through Week 12: Â± 3 days from the 
specified study day. Visit window Week 16: 1 week prior/+2 days from the 
specified study day.
 
Adverse Events 
Review X  
Ã…=====================================Ã†  X X After informed consent but prior to initiation of study drug, all AEs and SAEs related to protocol-mandated procedures 
should be reported.   
 All AEs and SAEs, regardless of cause or relationship, will be collected from the start of study drug through the Follow-Up 
Period.  
Concomitant 
Medications 
Review    
Ã…=====================================Ã†  X X  
Take Study Drug 
Capsules   
Ã…=====================================Ã†    Patients must be in fasted state for at least 
[ADDRESS_524740].  
a. If a patient requires home quarantine due to SARS-CoV-2 infection or exposure, or due to COVID-19 symptoms or other associated concern with attending an in-person study 
visit, home health care visits may be conducted to continue study assessments in the patientâ€™s home where feasible, and/or remo te visits via telephone, telemedicine, or other 
appropriate virtual communication may be substituted for a visit to the site.  
Protocol TERN201-1007 
Terns, Inc. 
 Version: Amendment 3 
Version Date: [ADDRESS_524741] 2021 
  
 
CONFIDENTIAL Page 18 of 92   b. Patients discontinuing the study at any time for any reason prior to  Week 12 (Early Termination) should complete the ET visit a s soon as feasible and return for a Follow-Up 4 
weeks (-1 week /+2 days) after the last dose of study drug.  
c. The Follow-Up may take place at Week 16 (-1 week /+2 days) or 4 weeks (-1 week /+2 days) after the last dose of study drug if p atients discontinue the study at any time for any 
reason prior to Week 12 (Early Termination).   
d. Samples collected during the treatment period should be collected pre-dose. 
e. In the event of symptoms suggest ive of COVID-19, ad hoc testing (including molecular test such as PCR or viral antigen serology , and/or antibody testing), may be completed at 
Investigatorâ€™s discretion.  
f. sVAP-[ADDRESS_524742] ed along with MRI cT1. 
h. If a patient is required to be quarantined due to active infection of COVID-19 or exposure to COVID-19, or is otherwise unable to visit the site due COVID-19, study drug may be 
mailed to the patient or made available via another appropriate mechanism (i.e., curbside pi[INVESTIGATOR_9107], etc.). See Section 6.8.1  for additional guidance in the event of hospi[INVESTIGATOR_221249]-19. 
Abbreviations:  AE = adverse event; ALT = alanine transaminase; AST = aspartate transaminase; BMI = body mass index; CK-18 = cytokeratin-18; C OVID-19 = coronavirus disease 2019; 
cT1 = corrected T1; ECG = electrocardiogram; ET = early termination; eGFR = estimated glomerular filtration rate;; FSH = follic le stimulating hormone; HA = hyaluronic acid; HbA1c = 
hemoglobin A1c; HBsAg = hepatitis B surface antigen; HCV = hepatitis  C virus; HIV = human immunodeficiency virus; hsCRP = high sensitivity C-reactive protei n; ICAM-1= intercellular 
adhesion molecule 1; INR = international normalized ratio; IWRS = interactive web resp onse system; MRI = magnetic resonance ima ging; MRI-PDFF = MRI-proton density fat fraction; PCR 
= polymerase chain reaction; PD = pharmac odynamics; PI[INVESTIGATOR_120861] = Procollagen III N-Terminal Propeptide; PK = pharmacokinetics; PRO- C3 = pro-peptide of type III collagen; ULN = upper 
limit of normal; SAE = serious adverse event; sVAP-1= soluble vasc ular adhesion protein-1; TIMP-1 = tissue inhibitor of metalloproteinases-1; VCAM-1 = vascular cell adhesion molecule 
1; WOCBP = women of childbearing potential.
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524743] 2021 
 
 
CONFIDENTIAL  Page 19 of 92  
 2. Introduction 
2.1. Overview of NASH and Role of VAP-1/SSAO in Disease 
Terns is developi[INVESTIGATOR_416439]-201, an i nvestigational, potent, and highly selective, irreversible 
covalent inhibitor of human vascular adhesion protein-1(VAP-1)/semicarbazide-sensitive amine 
oxidase for the treatment of  patients with non-alcoholic  steatohepatitis (NASH).  
NASH is an advanced form of non-alcoholic fa tty liver disease (NAFLD), the most common 
cause of chronic liver disease in North America ( Chalasani 2018 ). NASH is characterized by [CONTACT_416458], w ith or without fibrosis. NASH 
is a progressive condition that can lead to cirrhosis, decompensated liver disease, and increased risk for hepatic carcinoma and liver-related mortality ( Ekstedt 2015 ). Currently, there are no 
approved therapi[INVESTIGATOR_110235]. With an aging population and the emergence of 
overlappi[INVESTIGATOR_416440], diabetes, a nd dyslipi[INVESTIGATOR_035]/metabolic  syndrome, NAFLD and 
NASH have increased greatly in prevalence ( Andronescu 2018 ), posing a significant healthcare 
challenge. 
VAP-1/SSAO is a cellular adhe sion protein and ectoenzyme expressed on the vascular 
endothelium that has long been recognized as a mediator of leukocyte adhesion and 
extravasation in the setting of inflammation ( Salmi 2019 ). The enzymatic activity of VAP-1 
further contributes to inflammation and oxida tive stress by [CONTACT_416459], ammonia, and hydrogen pe roxide. VAP-1 levels are increased in the liver tissue and 
blood of patients with NASH a nd circulating VAP-1, termed soluble VAP-1 (sVAP-1), is 
independently associated with fibrosis stage ( Weston 2015 ). Genetic and pharmacology studies 
indicate VAP-1 defici ency or inhibition attenuate steatosis , inflammation, and fibrosis in NASH 
models. VAP-1 deficiency attenuates carbon tetrachloride (CCl4)-induced hepatic fibrosis and VAP-1 knockout mice exhibit reduced hepatic steatosis and fibrosis when fed a western lifestyle diet. Moreover, treatment with a VAP-1 antibody re duces inflammation, steatosis, and fibrosis in 
a methionine cholineâ€“deficien t diet mouse model of NASH ( Weston 2015).  
Based on these observations, VAP-1 inhibition is an ticipated to reduce inflammation and fibrosis 
in NASH patients. This novel mechanism provi des a potential opportunity to treat NASH, a 
disease with significant unmet medical needs.  
Of note, historically, VAP-1 has also been referred to as SSAO due to its sensitivity to inhibition 
by [CONTACT_416460], a property that distinguish es it from flavin adenine dinucleotide (FAD)-
containing monoamine oxidases (e.g., MAO-A and MAO-B) ( Smith 1998 ). In this document, the 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524744] 2021 
 
 
CONFIDENTIAL  Page 20 of 92  
 terms VAP-1 and SSAO (or VAP-1/SSAO) are used  interchangeably. Addi tional information on 
nomenclature is available in the Investigatorâ€™s Brochure. 
2.2. VAP-1/SSAO Inhibition in NASH and TERN-201 Background 
VAP-1 has been identified as a target for NAS H due to the inflammatory component of NASH 
pathogenesis, associatio n of increased VAP-1 levels in NAS H patients, and nonclinical studies 
supporting potential benefit in NASH from VAP -1/SSAO deficiency or suppression 
(Section 2.1 ). One other VAP-1/SSAO inhibitor has been studied in NASH patients 
(Study Registry ID: [REMOVED]). Pharma xis (Frenchs Forest, AUS) identified an 
oral VAP-1 inhibitor, BI 1467335 (formerly PXS- 4728A), which was advanced into clinical 
development for NASH by [CONTACT_416461]. Preliminary data s uggest dose-dependent 
reductions in alanine aminotransferase (ALT) a nd CK-18 with 12-weeks of  treatment with BI 
1467335, and an overall reassuring safe ty profile in NASH patients ( Study Registry ID: [REMOVED] ). In addition to its activity against VAP-1, BI 1467335 also inhibits monoamine 
oxidase B (MAO-B) ( Schilter 2015 ), albeit to a lesser extent, with potential implications for 
drug-drug interactions associated with monoa mine oxidase inhibition. In addition to NASH, 
VAP-[ADDRESS_524745] also been  explored for other indications including kidney disease. In a 
phase 2 study (ALBUM, ClinicalTrials.gov Id entifier: [STUDY_ID_REMOVED]), the VAP-1 inhibitor 
ASP8232 (Astellas Pharma) was e ffective at reducing albuminuria  in patients with diabetic 
kidney disease, suggesting the possibility of bene fit outside of liver, pe rhaps attributable to 
endothelial effects ( de Zeeuw 2018). 
TERN-201 is a potent, irreversible, highly specific inhibitor of VAP-1/ SSAO, formulated for 
oral administration in a capsule form. Nonclini cal studies have demons trated that TERN-[ADDRESS_524746] monoamine 
oxidase A or B. 
TERN-201 has been evaluated in an extensiv e nonclinical program, including PK, safety 
SKDUPDFRORJ\JHQRWR[LFLW\DQGUHS HDWGRVHWR[LFRORJ\WR[LFRNLQHWLFVWXGLHVRIXSWRà¯—ZHHNV
in duration. TERN-[ADDRESS_524747]-in-human (FIH) study (N=61), where it 
was found to be overall sa fe and well-tolerated.  
Below is a brief summary of these studies. Detailed results are available in the TERN-201 
Investigatorâ€™s Brochure. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524748] 2021 
 
 
CONFIDENTIAL  Page 21 of 92  
 2.2.1. Summary of Nonclinical Studies 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524749] 2021 
 
CONFIDENTIAL  Page 22 of 92   
 
 
 
 
 
 
 
  
   
 
 
 
 
 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524750] 2021 
 
 
CONFIDENTIAL  Page 23 of 92  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524751] 2021 
 
 
CONFIDENTIAL  Page 24 of 92  
  
 
 
 
 
 
  
 
 
 
2.2.2.
 Clinical Studie s of TERN-201 
The initial, FIH Phase 1 clinical study, TERN201-US-A101, was a double-blind, randomized, 
placebo-controlled study to investigate the sa fety, tolerability, pharm acokinetics (PK), and 
pharmacodynamics (PD) of single and multiple ascending oral doses of TERN-[ADDRESS_524752]  of food (high-fat/high-calorie 
meal) on the PK of TERN-201. Study TERN201-US-A101 was comprised of 3 parts. In Part A, 
4 single-ascending dose (SAD) cohorts (8 par ticipants each [6 TERN-201, 2 placebo]) were 
completed, in which participants received oral  TERN-201 or matching placebo doses of 1, 3, 6, 
or 10 mg. A fifth SAD cohort (20 mg) was plan ned but not enrolled due to public health 
restrictions resulting from the Coronavirus Di sease 2019 (COVID-19) pandemic. In Part B, 
3 multiple-ascending dose (MAD) cohorts (8 par ticipants each [6 TERN-201, 2 placebo]) were 
completed, in which participants received oral  TERN-[ADDRESS_524753] cohort, was 
initiated with 5 of the 16 planned participants enrolled; however, enrollment was discontinued 
early due to the -19 pandemic. The 5 participants enrolled in Part C received both doses of 
TERN-201 10 mg (single doses on Days 1 and 8, fed and fasted) as planned in the study 
protocol. 
During the study, no safety or tolerability concerns were identified, and no predefined stoppi[INVESTIGATOR_416441]. All AEs were Grade 1 or 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTC AE] Version 5.0) in severity. All AEs in 
participants who received TERN-[ADDRESS_524754] dermatitis at the site of electrocardiogram (ECG) leads that was considered unrelated to study drug, and headache (2 participan ts), all AE types were isolated to a single 
participant. There were no serious AEs, deaths , or AEs that led to di scontinuation of study drug 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524755] dose group (10 mg) after Day [ADDRESS_524756] of TERN-201 on 
VAP-1/SSAO-specific amine oxidase activity in the plasma, near complete inhibition (>80% 
with 1 mg, > 90% with 10 mg) was observed after only a single dose on Day 1 (achieved within 
4 hours after dosing) with sust ained suppression over the dosing period in MAD cohorts. Dose-
dependent increases in methylamine, an endog enous substrate of VAP-1/SSAO predicted to 
increase upon VAP-1/SSAO inhib ition, were observed after the first dose of TERN-201 and 
continued to increase in a dose-dependent manner after multiple doses of TERN-201.  
Based on the exploratory assessment on plas ma PK of two TERN- 201 metabolites, TRN-001021 
and TRN-001744, the percentages of  either metabolite AUC relative to the total TERN-201-
related plasma AUC (sum of TERN-201, TRN-001021, and TRN-001744) were calculated. Median TRN-001021 AUC was <10% and 13.7% of the total plasma AUC associated with 
TERN-201 in the 4 mg and 10 mg groups, re spectively. Median TRN-001744 AUC was 11.5% 
and <10% of the total plasma AUC associated with TERN-201 in the 4 mg and 10 mg groups, respectively. 
Additional details on Study TERN201-US-A101 are av ailable in the Investigatorâ€™s Brochure. 
2.3. Benefit/Risk Assessment 
 
 
 
 
 
  
 
  
 
 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524757] that proj ected exposures are below the 
limits noted above. 
Taking into account the measures taken to minimize risk to patients in this study, the potential 
risks identified in association with TERN-201 are justified by [CONTACT_416462]. 
Please refer to the Investigatorâ€™s Brochure for a summary of data on TERN-201 and guidance for 
Investigators.   

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524758] 2021 
 
 
CONFIDENTIAL  Page 27 of 92  
 3. Objectives and Endpoints 
Primary Objective:  
x To characterize the safety and tolerability of TERN-201 versus placebo for 12 weeks in 
non-cirrhotic presumed NASH patients, with a clinical or histological NASH diagnosis 
Secondary Objectives: 
x To assess the plasma and urine PK of TERN -[ADDRESS_524759] of TERN-201 vers us placebo for 12 weeks on plasma VAP-
1/SSAO activity in non-cirrhotic  presumed NASH patients 
Exploratory Objectives: 
x To assess the plasma and urine PK of TERN-201 metabolites (including TRN-001021 
and TRN-001744) at steady state 
x To assess the effect of TERN-[ADDRESS_524760] of TERN-201 versus  placebo on biomarkers of inflammation 
x To explore the potential for TERN-201 to impr ove proteinuria due to  endothelial effects 
x To explore other PD markers, and ove rall exposure-response and dose-response 
relationship of TERN-201, as applicable  
x To explore the exposure-response and dose-re sponse relationship, as applicable, of 
TERN-201 and baseline patient characteristic s such as soluble VAP-1 (sVAP-1), body 
mass index (BMI), diabetes mellitus, and others  
Endpoints:  
Primary Endpoint:  
x Overall safety assessed by [CONTACT_416457] (TEAEs), and treatment emergent 
clinical safety labo ratory abnormalities  
Secondary Endpoints:  
x Plasma and urine PK pa rameters for TERN-201  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524761] 2021 
 
 
CONFIDENTIAL  Page 28 of 92  
 x Percent change from baseline in plasma VAP-1/SSAO activity 
Exploratory Endpoints:  
x Plasma and urine PK parameters for TERN-201 metabolites (i ncluding TRN-001021 and 
TRN-001744) 
x Change from baseline in corrected T1 (cT1) by [CONTACT_9252] (MRI) 
x Change from baseline in liver fat content by [CONTACT_9252]-proton density 
fat fraction (MRI-PDFF) 
x Change from baseline in stiffness by [CONTACT_331436]  
x Change from baseline in alanin e aminotransferase (ALT)  
x Change from baseline in gamma-glutamyl transpeptidase (GGT) 
x Change from baseline in aspart ate aminotransferase (AST) 
x Change from baseline in NASH and fibrosis biomarkers including cytokeratin-18 (CK-
18) (M30 and M65), procollagen III n-terminal propeptide (PI[INVESTIGATOR_120861]), tissue inhibitor of metalloproteinases-1 (TIMP-1), hyaluronic ac id (HA), pro-peptide of type III collagen 
(PRO-C3), and type III collagen (C3M). Other non-invasive tests for NASH fibrosis may also be assessed including the fibrosis-4 (FIB-4 ) index, enhanced liver fibrosis (ELF) test, 
NAFLD fibrosis score (NFS), and PRO-C3/C3M ratio. 
x Change from baseline in inflammatory biom arkers including high sensitivity C-reactive 
protein (hs-CRP), interleukin-6 (IL-6), intercellular adhesion mole cule-1 (ICAM-1), and 
vascular cell adhesion molecule-1 (VCAM-1) 
x Change from baseline in estimated glomerular filtration rate (eGFR), urine protein including urine protein-to-creatinine ratio (U PCR), and urine albumin-to-creatinine ratio 
(UACR)  
x Change from baseline in plasma methylamine levels (PD marker of VAP-1/SSAO inhibition) 
x Exposure-response and dose-response rela tionship of TERN-201 over 12 weeks, as 
applicable  
x Exposure-response and dose-response relations hip, as applicable, of TERN-201 and 
baseline patient characteristics such as sVAP-1, BMI, diabetes mellitus, and others 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524762] 2021 
 
 
CONFIDENTIAL  Page 29 of 92  
 4. Study Design 
4.1. Overall Design 
The study is a multi-center, randomized, doubl e-blind, placebo-controlled, adaptive study. 
Approximately 80 clinically or histologically diagnosed adult non-cirrhotic presumed NASH 
patients who meet study eligibility criteria will be enrolled and ran domized at an overall ratio of 
2:1 in up to 3 dose groups and placebo across 2 parts of the study. 
Part 1  In Part 1, approximately 30 pa tients will receive 10 mg TERN- 201 (n = 20) or matching placebo 
(n = 10) orally once daily, for 12 weeks. Part 2 may be enrolled based on an interim analysis, as 
follows: 
In Part [ADDRESS_524763] dose (Week 0/Day 1), at Week 6, and after the last dose of study 
drug (Week 12). Randomization will ensure a pproximately 8 patients in the TERN-201 group 
and approximately 4 pati ents in the placebo group are assi gned to the PK/PD sub-study. Patients 
who are not participating in the PK/PD s ub-study will have trough PK/PD sampling only. 
An interim analysis will be performed after all patients in Part [ADDRESS_524764] completed Week 6 
assessments. Interim PK and PD data will be assessed. Blinded safety data will also be reviewed. Enrollment of cohorts to a ssess 4 mg and up to 20 mg TER N-201 may be initiated per the 
following criteria:  
x TERN-201 4 mg:  
o If robust VAP-1/SSAO activity suppression is observed and available PK from 
Part [ADDRESS_524765] VAP-1/SSAO 
activity suppression, enrollment in Part 2 with 4 mg TERN-201 may be initiated.  
x TERN-201 up to 20 mg: 
o If safety data indicates 10 mg TERN-201 is overall safe and well-tolerated, and 
available PK from Part 1 predicts that ta rgeted exposures for a dose up to 20 mg 
will be below an upper limit of 5400 ngâ€¢hr/mL for AUC
0-24hr and 768 ng/mL for 
Cmax, enrollment in Part 2 with a dose up to 20 mg TERN-201 may be initiated. 
Part 2  
In Part 2, if initiated, approximately 50 patients will receive 4 mg TERN-201 (n = 20), and/or up 
to 20 mg TERN-201 (n = 20), or matching placebo (n = 10) orally once daily, for 12 weeks. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524766] dose (Week 0/Day 1), at Week 6, and after the last dose of study 
drug (Week 12). Randomization will ensure a pproximately 6 patients at each TERN-201 dose 
level and approxima tely 3 patients in the placebo group ar e assigned to the PK/PD sub-study.  
The total duration of study participation will be approximately 22 weeks, consisting of a 6-week 
Screening Period, a 12-week Treatment Period and a 4-week Follow-up Period.  
4.2. Scientific Rationale for Study Design 
Collectively, results from nonclinical studi es and FIH study, TERN201-US-A101, support the 
development of TERN-201 as an orally ad ministered VAP-1/SSAO inhibitor to reduce 
inflammation and fibrosis in the liver of pa tients with NASH. TERN-[ADDRESS_524767] dose studied in the FIH study (10 
mg TERN-201), which was safe a nd well-tolerated and will allow for the PD effect of TERN-
201 (e.g., inhibition of plasma VAP-1/SSAO activity) to be assessed in the NASH population. 
 
 
 
 
The placebo-controlled nature of the study will allow for a control group to characterize the 
safety and preliminary efficacy of TERN-201 in  a NASH population. Given the efficacy of 
TERN-201 has not yet been confir med, there is no clear detrime nt to patients who may be 
randomized to receive placebo rather than active treatment in this study. 
The study will enroll a non-cirrhotic presumed NASH population based on clinical 
characteristics and imaging (wit hout a requirement for liver biops y), to characterize safety and 
efficacy in this population. While there is not an expected risk of neurol ogical toxicity at the 
clinical doses proposed based nonclinical toxicity studies a nd the FIH study, patients with a 
history of seizures and select other co-morbidities will be excluded to avoid interference from 
disease processes in the safety assessment of TERN-201 in this study.  

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524768] 2021 
 
 
CONFIDENTIAL  Page 31 of 92  
 4.3. Justification for Dose 
Doses for this study were based on results from the FIH Phase 1 study, TERN201-US-A101, 
which evaluated 4 SAD cohorts of TERN-201 or matching placebo at 1 mg, 3 mg, 6 mg, or 
10 mg, and 3 MAD cohorts of TERN-201 or matchi ng placebo at 1 mg for 7 days, 4 mg for 
7 days, or 10 mg for 14 days.  
In the FIH study, single or multiple doses of TER N-201 resulted in rapid inhibition of plasma 
amine oxidase activity, with sustained inhibition during 14 days of dosing. TERN-201 
demonstrated a favorable safety  profile and was overall well-tolerated at all doses studied 
(Section 2.2.2). 
Part [ADDRESS_524769] dose studied in the FIH study. In the FIH study, this dose led to >90% suppres sion of plasma VAP-1 /SSAO-specific amine 
oxidase activity in healthy participants. NASH pa tients are expected to have a higher baseline 
level of VAP-1, and thus the PD  effect of TERN-[ADDRESS_524770] of TERN-201 on plasma VAP-1 /SSAO activity in the 10 mg cohort, thus 
minimizing the number of patients exposed until the PK and PD effects of TERN-201 can be 
confirmed in Part 1 of the study.  
Toxicity and safety pharmacology studies support starting with the 10 mg dose and enrolling a 
higher dose up to 20 mg. 
 
 
 
 
 
  
 
Additional details on availa ble data from Study TERN201-US-A101 are provided in the 
TERN-201 Investigatorâ€™s Brochure. 

Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524771] 2021 
 
 
CONFIDENTIAL  Page 32 of 92  
 5. Study Population 
Prospective approval of protocol  deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1. Inclusion Criteria 
Patients are eligible to be in cluded in the study only if all of the following criteria apply at 
Screening:  
1. Must be 18 to 75 years of age inclusive, at the time of signing the informed consent 
2. Male or female, willing to follow contraception requireme nts defined by [CONTACT_18113] 
(Appendix 7); female patients of childbearing pot ential must also have negative serum 
pregnancy test, not be breastf eeding, and not plan to become pregnant during the study or 
within [ADDRESS_524772] dose of study drug 
3. 2YHUZHLJKWRUREHVHZLWKD%0,Â•NJP2  
4. NASH by [CONTACT_416463]:  
a. For clinical diagnosis:  
i. Step 1: Liver stiffness measured by [CONTACT_416464] 6.5 - 21 kPa 
and controlled atte nuation parameter (CAP) > 280 dB/m within 3 months 
prior to Screening (if results available within this timeframe, assessment does not need to be repeated at Screening). 
ii. Step 2: Patients meeting these and a ll other eligibility criteria will undergo 
MRI cT1 and must have a cT1 value > 800 ms for randomization.  
b. For biopsy diagnosis:  
i. Step 1: Fibrotic NASH (NASH CRN F1, F2, or F3) without cirrhosis 
diagnosed by [CONTACT_242828] [ADDRESS_524773] able weight (< 5% weight loss) 
since the time of the biopsy. Results from a previous study end of treatment biopsy are permissible if drug was deemed non-therapeutic or 
patient received placebo. 
ii. Step 2: Patients meeting these and a ll other eligibility criteria will undergo 
MRI cT1 and must have a cT1 value > [ADDRESS_524774]: 
x $/7Â• 43 U/L for men DQGÂ•8 U/L for women 
x MRI-cT1 liver inflammation > 800 ms 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524775] 2021 
 
 
CONFIDENTIAL  Page 33 of 92  
 6. Capable of giving signed informed consent as described in Section 10.1.2 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol 
5.2. Exclusion Criteria  
Patients are excluded from the study if any of the following criteria apply at Screening: 
Medical Conditions 
1. History or clinical evidence of chronic liver diseases other than NAFLD or NASH 
including but not limited to: 
x Active hepatitis B virus (HBV) infection defined as positive HBV surface antigen at screening  
x Active hepatitis C virus (HCV) infecti on defined as positive HCV antibody (anti-
HCV) and HCV ribonucleic acid (RNA). Patients with anti-HCV but negative 
HCV RNA will be eligible for participation if HCV RNA has been negative for at least 1 year. 
x Autoimmune liver disease 
x Primary biliary cirrhosis 
x Primary sclerosing cholangitis 
x Wilsonâ€™s disease (history should incl ude normal serum ceruloplasmin and 24-
hour urinary copper) 
x Gilbertâ€™s syndrome  
x Hemochromatosis or other iron overload  
x Alpha-1-antitrypsin (AAT) deficiency (history should include normal AAT genotype and serum AAT level) 
x Alcoholic liver disease 
x Prior known drug-induced  hepatotoxicity 
x Known bile duct obstruction 
x Suspected or proven liver cancer  
2. History or clinical evidence of cirrhosis, he patic decompensation, or  other severe liver 
impairment, including ascites, hepatic encephalopathy, and variceal bleeding 
3. History of liver transplant, or current  placement on a liver transplant list 
4. ALT or AST > 5 Ã— upper limit of normal (ULN)  
5. Unstable elevated ALT or AST. Patients with ALT or AST > 60 IU/L must have 
evidence of a stable ALT and AST over at least a 2-week time period prior to randomization as evidenced by [CONTACT_080]:  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524776] (histori cal values) obtained within 2-12 weeks 
prior to the Screening visit: Screening ALT and AST values VKRXOGEHÂ”
higher than a documented prior result, OR 
x Repeat ALT and AST values at least 2 weeks after the Screening visit: Repeat 
ALT and $67VKRXOGEHÂ”KLJKHUWKDQWK e values from the Screening visit, 
and the repeat values must be Â” 5 Ã— ULN 
x If the Investigator has clinical suspi[INVESTIGATOR_416442] r acute liver injury in a patient for other 
reasons, the patient should be excluded afte r discussion with the Medical Monitor. 
x The MRI cT1 may proceed on the basis of the initial ALT and AST values at Screening, given all other e ligibility criteria are met, but randomization should not 
occur prior to confirmation of ALT and AST stability, as necessary.  
 
6. Total bilirubin > 1.2 mg/dL  
7. Albumin < 3.3 g/dL  
8. International normalized ratio (INR) > 1.3 
9. Alkaline phosphatase (ALP) > 159 IU/L 
10. Platelet count < 150,000 /mm
3 
11. eGFR < 60 mL/min/1.73m2   
12. Weight loss of > 5% total body weight within 3 months prior to Screening 
13. History of a malignancy within 2 years of  Screening, with the following exceptions:  
a) Adequately treated carcinoma in situ of the cervix 
b) Adequately treated basal or  squamous cell cancer or other localized non-melanoma 
skin cancer  
14. Uncontrolled diabetes with hemoglobin A1c (HbA1c) > 9.5% or actively undergoing 
anti-diabetes medication titration (see Exclusions 35, 36, and 39 for additional details). Note: Patients with or  without diabetes may be enrolled provided all e ligibility criteria 
are met.  
15. Average weekly alcohol consumption of > [ADDRESS_524777] drinks for males and > [ADDRESS_524778] drinks for females over a period of more than 3 consecutive months in the year 
prior to Screening. Remote history of alcoholism with abstinence > 12 months prior to Screening and no history of alcoholic  liver disease is permissible.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524779] 2021 
 
 
CONFIDENTIAL  Page 35 of 92  
 Note: A standard drink is defined as 12 oz  (360 ml) beer, 1.5 oz (45 ml) liquor, or 5 
oz (150 ml) wine.  
16. Illicit substance/chemical abuse in the 12 months prior to Screening 
17. Cannabis use (tetrahydrocannabi nol [THC] and cannabidiol [CBD]) within 14 days of 
randomization 
18. Unwilling to abstain from excessive alcohol use (defined in #15 above), cannabis use, 
and illicit substance use during study participation 
19. Positive for human immunodeficiency virus (HIV) infection 
20. QTcF > 450 ms for males, > 470 ms for females 
21. Unstable cardiovascular di sease defined as myocardial  infarction, unstable angina, 
percutaneous intervention, corona ry artery by[CONTACT_9292], or stroke within 6 months prior 
to randomization 
22. [LOCATION_001] Heart Association class III or IV heart failure, or know left ventricular 
ejection fraction < 30% 
23. Uncontrolled hypertension defined as systolic blood pressure > 160 mmHg or a 
diastolic blood pressure > 100 mmHg (treated or untreated) on at least two occasions 
more than 10 minutes apart 
24. History of hypotension including orthostatic or postprandial hypotension  
25. History of seizure disorder 
26. History of known or suspected serotonin syndrome 
27. Schizophrenia or bipolar disorder 
28. Parkinsonâ€™s disease  
29. Known or suspected pheochromocytoma 
30. Known allergy to study drug  
31. Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions  
32. Laboratory or clinical evidence of current infection with Severe  Acute Respi[INVESTIGATOR_81370] 2 (SAR S-CoV-2), i.e., COVID-19 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524780] 2021 
 
 
CONFIDENTIAL  Page 36 of 92  
 33. Presence of any condition that could, in the opi[INVESTIGATOR_689], compromise the 
patientâ€™s ability to participate in the study 
Prior Therapy 
34. Use within 6 months prior to Screening: Treatment with monoamine oxidase inhibitors 
including but not limited to isoniazid, linezolid, methylene blue, tranylcypromine, 
isorboxazid, phenelzine, selegiline, rasagiline, safinamide; these therapi[INVESTIGATOR_416443]-up per  Section 6.6  
 
35. Use within 3 months prior to Screening: obeticholic acid, SLRJOLWD]RQHRURWKHU33$5È–
agonists, or high-dose vitamin E (> 400 IU/day); these therapi[INVESTIGATOR_416443]-up per  Section 6.6   
36. Initiation or dose adjustment within 3 months prior to Screening (i.e., must be on stable dose for 3 months prior to Screening):  
x GLP-1 analogues, DPP-4 inhibitors, and SGLT2 inhibitors  
x 9LWDPLQ(Â”,8GD\   
37. Use within 3 months prior to Randomization: 
x Medications potentially impacting steatohepatitis, including but not limited to systemic corticosteroids (p rednisone equivalent of > 10 mg/day for > 2 weeks), 
amiodarone, tamoxifen, and methotrexate; these therapi[INVESTIGATOR_416444]-up per Section 6.6  
38. Initiation or dose titration within 3 months prior to Randomization: 
x Hormonal contraceptives 
39. Initiation or dose titration within 2 months prior to Randomization (i.e., must be on 
stable dose for 2 months prior to Randomization): 
x Metformin and other antidiabetic drugs not described above. 
40. Use within 2 weeks prior to Randomization:  
x Oral creatine supplementation; this is also prohibited from randomization 
through end of study follow-up per Section 6.6  
x Vaccination for influenza, COVID-19, or other routine vaccinations 
x Potent CYP3A inducers or inhibitors; th ese therapi[INVESTIGATOR_416445]-up per Section 6.6  
Prior Clinical Study Experience 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524781] 2021 
 
 
CONFIDENTIAL  Page 37 of 92  
 41. Participation in another clinical trial within 3 months or 5 half-lives of the other 
investigational agent (whichever is longer) prior to randomization. Patients who can demonstrate they did not receive active drug or who received an investigational treatment that was deemed non-th erapeutic during clinical tria l participation are eligible 
for enrollment 
5.3. Lifestyle Considerations 
Contraceptives or other means of birth control are required for patients of childbearing potential 
during study participation (see Appendix 7). 
5.3.1. Lifestyle Counseling 
Guidance should be provided on key elements of a healthy lifestyle at each visit including diet, 
exercise, weight loss, and avoidan ce of alcohol per standard of ca re management for this patient 
population.  
5.3.2. Meals and Dietary Restrictions 
Patients should arrive at the c linic fasting for assessments and study drug administration as 
defined in the Schedule of Activities ( Section 1.3 ). This includes at least an 8-hour fast prior to 
the visit, during which food and drink is re stricted. Water is allowed ad libitum.  
On all other days, patients will self-administer the study drug orally once daily in the morning on 
an empty stomach, after an 8-hour fast. 
Patients participating in the PK/PD sub-study at Week 0/Day 1, Week 6, and Week 12 should 
arrive at the clinic fasting (an 8-hour fast prior to the visit) a nd restrict food and drink until [ADDRESS_524782]-dose. Food and drink ma y resume after this timepoint. Patients particip ating in the 
PK/PD sub-study do not need to be fasting for blood collection at 24, 48, or [ADDRESS_524783] agree to not consume > [ADDRESS_524784]  drinks per week for males and > [ADDRESS_524785] drink is defined as 12 oz (360 ml) beer, 1.5 oz (45 ml) 
liquor, or 5 oz (150 ml) wine.  Patients must abstain from TH C (cannabis) and illicit drug use during study participation.  
Patients must abstain from CBD use during study participation. Short te rm topi[INVESTIGATOR_416446] 
(< 14 days) is acceptable.   
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524786] 2021 
 
 
CONFIDENTIAL  Page 38 of 92  
 5.4. Screen Failures 
Screen failures are defined as patients who consent to participate in the clinical study but are not 
subsequently randomized. A minimal set of screen failure information is required and will be documented to ensure transparent reporting of sc reen failure patients to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing require ments and to respond to queries 
from regulatory authorities. Min imal information includes demogr aphy, screen failure details, 
eligibility criteria, and any serious adverse event (SAE). 
An otherwise eligible patient who is completing a vaccination series prior to enrollment may 
have the Screening window extended to a llow for vaccination completion; laboratory 
assessments to confirm eligibility should be repeated if th e Screening window has been 
exceeded. An otherwise eligible patient who screen fails due to SARS-CoV-[ADDRESS_524787] be discussed with the Sponsor.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524788] 2021 
 
 
CONFIDENTIAL  Page 39 of 92  
 6. Study Drug 
Study drug is defined as any investigational intervention(s), mark eted product(s), or placebo 
intended to be administered to a study pa tient according to the study protocol. 
6.1. Study Drug(s) Administered 
Investigational 
Medicinal Product TERN-201 capsules Placebo-to-match (identical in shape, size, appearance, and color to TERN-201 capsules)  
Type  Drug Drug 
Dose Formulation Capsule Capsule 
Unit Dose 
Strength(s) 1, 3, or 10 mg per capsule Matching placebo per capsule 
Route of Administration Oral Oral 
Use Experimental Placebo  
IMP/NIMP  IMP  IMP  
Sourcing  Provided centrally by [CONTACT_416465] a labeled carton that contains HDPE bottle(s). In Part 1, each carton will contain one bottle for 4-week usage. In Part 2, each carton will contain two bottles for 4-week usage.  Each bottle will be labeled as required per country requirements.  Study drug will be provided in a labeled carton that contains HDPE bottle(s). In Part 1, each carton will contain one bottle for 4-week usage. In Part 2, each carton will contain two bottles for 4-week usage. Each bottle will be labeled as required per country requirements.  
Abbreviations:  HDPE = High-density polyethylene; IMP = investigational medicinal product; NIMP = non 
investigational medicinal product  
6.2. Study Drug Administration  
Patients will be instructed to take capsules as shown in Table 1.   
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524789] 2021 
 
 
CONFIDENTIAL  Page 40 of 92  
 Table 1 Study Drug by [CONTACT_416466]-201 Capsules Placebo-to-Match 
Part 1 â€“ 10 mg One 10-mg capsule QD  One placebo capsule QD  
Part 2 â€“ 4 mg One 1-mg capsule and one 3 mg 
capsule QD  Two placebo capsules QD 
Part 2 â€“ 20 mg Two 10-mg capsules QD  Two placebo capsules QD 
Abbreviations:  QD = once per day 
6.3. Preparation/Handling/Storage/Accountability 
The Investigator or designee must provide ackno wledgement of receipt of each shipment of 
study drug including appropria te temperature conditions have b een maintained during transit for 
all study drug received and any disc repancies are reported and reso lved before use of the study 
drug. 
Only patients enrolled in the study may receive study drug and only authorized site staff may 
supply or administer study drug. All study drug must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Inves tigator and authorized site staff. 
The Investigator, institution, or the head of the medical institution (w here applicable) is 
responsible for study drug accountability, reconcil iation, and record maintenance (i.e., receipt, 
reconciliation, and final disposition records). 
Further guidance and information for the final disposition of unused study drugs are provided in 
the Pharmacy Manual.  
6.4. Measures to Minimize Bias: Randomization and Blinding 
Patients will be randomized to TERN-201 or placebo using an In teractive Web Response System 
(IWRS). Before the study is initiated, the log-in information and directions for the IWRS will be 
provided to each site. 
Approximately 80 patients will be enrolled in this study. In Pa rt 1, approximately  30 patients will 
be randomized at a ratio of 2:1 to receive 10 mg TERN-201 (n = 20) or matching placebo (n = 
10). In Part 2, if initiated, a pproximately 50 patients will be randomized at a ratio of 2:1 to 
receive 4 mg TERN-201 (n = 20), and/or 20 mg  TERN-201 (n = 20), or matching placebo (n = 
10). Randomization will be stratified by [CONTACT_416467]1 values Â” 900 ms versus > 900 ms. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524790] dose of study drug. Randomization will 
ensure approximately 6 patients in the TERN-201 group and approximately  6 patients in the 
placebo group are assigned to the PK/PD sub-study. Patients who are not pa rticipating in the 
PK/PD sub-study will have trough PK/PD sampling only. 
In Part [ADDRESS_524791] dose of study drug. Randomization will 
ensure approximately 6 patients at each TERN-201 dose level and approximately 3 patients in 
the placebo group are assigned to the PK/PD sub-st udy. Patients who are not participating in the 
PK/PD sub-study will have trough PK/PD sampling only. 
Investigators, patients, all study personnel, and the Sponsor will rema in blinded to each patientâ€™s 
assigned dose group throughout the course of the study, unless otherwise specified in 
Section 6.4.1. Study drug will be dispensed at the study visits as summarized in Schedule of 
Activities. Returned study drug should not be re-dispensed to patients.  A planned interim analysis will be  conducted after all pa tients in Part [ADDRESS_524792]  completed Week 6 
assessments, and an administrativ e interim analysis may be conducted after the completion of 
Part 1 of the study. For these analyses, the study team will be blinded at the individual patient 
level, with designated personnel responsible for producing th e summary results. The details will 
be addressed in a separate plan.  
6.4.1. Unblinding 
Treatment assignment may be unb linded if knowing the patientâ€™s  treatment assignment would 
affect immediate medical management of the patient. The IWRS will be programmed with blind-
breaking instructions. In case of an emergency, the Investigator has the sole responsibility for 
determining if unblinding of a patie ntâ€™s intervention assignment is warranted. Patient  safety must 
always be the first consideration in making such a determination. If the I nvestigator decides that 
unblinding is warranted, the Investigator should make  every effort to contact [CONTACT_416468] a patientâ€™s intervention assignment unle ss this could delay em ergency treatment of 
the patient. If a patientâ€™s intervention assignm ent is unblinded, the Sponsor must be notified 
within [ADDRESS_524793] be recorded in the source documentation and case report form, as applicable. 
Any unblinding of Sponsor personnel for expedite d reporting of suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) or other reasons including planned interim analyses will be addressed in a se parate plan.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524794] udy Drug Assignment 
It is the responsibility of the Investigator to ensu re that patient eligibility  is confirmed prior to 
randomization. Documentation of the personally signed and dated informed consent of each 
patient, using the study-specific ICF, is requi red before initiating the Screening Period.  
After written informed consent has been obtained, the patientâ€™s identification number will be 
obtained from the IWRS. Once eligibility to par ticipate has been established, the randomized 
treatment assignment will be obtained from the IWRS. 
6.5. Study Drug Compliance 
Patients will be dispensed study during their study visits and w ill self-administer study drug at 
home. Patients must be in fasted  state for at least [ADDRESS_524795] questioning and counting returned capsules during the 
study visits and documented in the source docu ments and electronic cas e report form (eCRF). 
Deviation(s) from the prescribed dosage regimen should be recorded in the eCRF.   
If a patient is required to be quarantined due to active infection of COVID-19 or exposure to 
COVID-19, or is otherwise unable to visit the site due to COVID-19, study drug may be mailed 
to the patient or made available via another a ppropriate mechanism (i.e ., curbside pi[INVESTIGATOR_9107], etc). 
Patients will be asked to  maintain records of self-administered drug on non-study visit days. A 
record of the number of study drug capsules disp ensed to and taken by [CONTACT_416469]. Study drug start 
and stop dates, including dates for delays will also be recorded in the eCRF. 
6.6. Concomitant Therapy 
Any medication or vaccine (including over-the-c ounter or prescription medicines, vitamins 
and/or herbal supplements) that the patient is receiving at the time of randomizati on or receives 
during the study must be recorded at each study visit along with: 
x Reason for use 
x Dates of administration in cluding start and end dates 
x Dosage information incl uding dose and frequency 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524796] 2021 
 
 
CONFIDENTIAL  Page 43 of 92  
 Medications prohibited from randomization through end of study follow-up:  
x Monoamine oxidase inhibitors includi ng isoniazid, linezolid, methylene blue, 
tranylcypromine, isorboxazid, phenelzine, selegiline, rasagiline, safinamide  
x Medications with potential impact on NASH outcome, including obeticholic acid, 
pi[INVESTIGATOR_416447] È– agonists, or high-dose vitamin E (> 400 IU/day) 
o 3DWLHQWVUHFHLYLQJÂ”,8GD\SU LRUWRVWXG\VKRXOGQRWKDYH GRVHDGMXVWPHQW
on-study  
x Medications potentially impacting steatohepatitis, including but not limited to systemic 
corticosteroids (prednisone equivalent of > 10 mg/day for > 2 weeks), amiodarone, 
tamoxifen, and methotrexate. Use of systemic corticosteroids for < 2 weeks within 
3 months prior to randomization and while on study is allowed. 
x Oral creatine supplementation 
x Potent inducers or inhibitors of CYP3 A; a noncomprehensive list for known CYP3A 
strong inducers and inhibitors is provided below: 
o Potent CYP3A inhibitors prohibited on study include but are not limited to: 
boceprevir, cobicistat, rit onavir, grapefruit juice, itraconazole, ketoconazole, 
posaconazole, telaprevir, telithromy cin, troleandomycin, voriconazole, 
clarithromycin, idelalisib, ne fazodone, and nelfinavir 
o Potent CYP3A inducers prohibited on study include but are not limited to: 
apalutamide, carbamazepi[INVESTIGATOR_050], enzalutamide, mitotane, phenytoin, rifampin, and St. Johnâ€™s wort 
o Patients who require initiation of potent CYP3A inducers and inhibitors during 
the study should discontinue study drug. For patients who subsequently discontinue prohibited me dications, study drug administration may not be 
resumed unless discussed w ith the Medical Monitor. Patients who do not resume 
study drug should continue in the study for Follow-Up. 
x Other investigational agents 
All other medications not listed above are accep table for use from randomization through end of 
study follow-up. The Medical Monitor should be cont acted if there are any questions regarding 
concomitant therapy.  
6.7. Dose Modifications 
Dose modifications of st udy drug are not permitted.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524797]. If a patient forgets to self-administer study 
drug in the morning on a given day, the dose can be taken on the same day when the patient 
remembers, with the exception below:  
x For patients participating in the PK/PD s ub-study, drug must be se lf-administered the 
morning of the day prior to the Week 6 and We ek 12 visits. If not, the visit should be re-
scheduled for the following day. 
If a patient forgets to self-administer study drug on a given day, it will be designated a missed 
dose. Dosing may continue orally once daily acco rding to the protocol schedule after a missed 
dose.  
If study drug is discontinued or suspended for sa fety reasons considered related to study drug, 
dosing should not be resumed w ithout consultation with the Me dical Monitor. Information on 
stoppi[INVESTIGATOR_416448]/other reasons is detailed in Section 7 .  
6.8.1. Dose Interruptions due to COVID-19 
If a patient requires home quarantine due to SARS -CoV-2 infection or exposure, or due to 
COVID-19 symptoms, the patient may continue study drug provide d that appropriate safety 
follow-up is possible, and that hospi[INVESTIGATOR_416449]. Home health  care visits may be 
conducted to continue study assessments in the patientâ€™s hom e where feasible, and/or remote 
visits via telephone, tele medicine, or other appropriate virt ual communication may be substituted 
for a visit to the site. Sites should discuss the mechanism for safety follow-up with the Medical 
Monitor. If a patient has symptoms of COVID-[ADDRESS_524798] be 
discontinued during hospi[INVESTIGATOR_059]. A case-by-case  assessment of whethe r to resume study drug 
can be done upon discharge. Dosing should not be resumed without c onsultation with the 
Medical Monitor. The patient should be encouraged  to remain in the study to be evaluated during 
the Follow-Up Period.  
6.9. Intervention after the End of the Study 
No further interventions are plan ned after the end of the study.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524799] 2021 
 
 
CONFIDENTIAL  Page 45 of 92  
 7. Discontinuation of Study Drug and Patient 
Discontinuation/Withdrawal 
7.1. Discontinuation of Study Drug 
Study drug must be discontinued for an indi vidual patient in the following instances:  
x If an AE of Grade 3 or above (National Ca ncer Institute (NCI) CTCAE 5.0) occurs and 
is considered related to study drug as judge d by [CONTACT_416470] 6 
x Symptoms of COVID-19 requiring hospi[INVESTIGATOR_059] 
x Change in clinical status that, in the judgement of the Investigator compromises the 
patientâ€™s ability to continue treatment or is not considered to be in the patientâ€™s best interest  
x Patient request to disconti nue study drug for any reason 
x Pregnancy during the study (refer to Appendix 7 ) 
x Sponsor discretion  
x Discontinuation of the study at the request of the Sponsor, a regulatory agency, or 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Resumption of study drug may be considered in  discussion with the Medical Monitor and 
Sponsor. 
If one of the following situations occurs and is  considered related to the study drug without 
alternative etiology, study drug may be discontinued at the discretion of the Investigator and the 
Medical Monitor should be informed (with repeat test performed within 48-72 hours once initial 
abnormality is detected): 
x ALT or AST > 8 Ã— ULN  
x ALT or AST > 5 Ã— ULN for more than [ADDRESS_524800] > 2 Ã— Baseline with the appe arance of fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophilia > 5% 
x ALT or AST > 2 Ã— Baseline and total bilirubin > 2 Ã— ULN or INR > 1.[ADDRESS_524801] udy drug or study assessments. 
If study drug is permanently discontinued, the patie nt will remain in the study to be evaluated 
during the Follow-Up Period. See the Schedule of Ac tivities for data to be collected at the time 
of discontinuation of study drug a nd follow-up and for any further evaluations that need to be 
completed. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524802] 2021 
 
 
CONFIDENTIAL  Page 46 of 92  
 7.2. Patient Discontinuation/Withdrawal from the Study 
A patient may withdraw from the study at any time at his/her own request or may be withdrawn 
at any time at the discretion of the Investigator for safety, behavioral, compliance, or 
administrative reasons.  
Patients discontinuing the study at any time for any reason prior to Week 12 (Early Termination) 
should complete the early termination (ET) visit as soon as feasible and return for a Follow-Up 
approximately [ADDRESS_524803] dose of study drug. See the Schedule of Activities for data to be collected at the time of study discontinua tion and follow-up and for any further evaluations 
that need to be completed. 
If the patient withdraws consent for disclosure of  future information, the Sponsor may retain and 
continue to use any data collected be fore such a withdrawal of consent. 
If a patient withdraws from the study, he/she may request destruction of any samples taken and 
not tested, and the Investigator must doc ument this in the site study records. 
7.3. Lost to Follow up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for a 
scheduled visit and is unable to  be contact[CONTACT_9298]. 
The following actions must be taken if a patient fails to return to the clinic for a required study visit: 
x The site must attempt to c ontact the patient and reschedul e the missed visit as soon as 
possible, counsel the patient on the impor tance of maintaining the assigned visit 
schedule, and ascertain whether or not the pa tient wishes to and/or should continue in 
the study. 
x Before a patient is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact [CONTACT_413845] (where possible, 3 telephone calls and, if 
necessary, a certified letter to the patientâ€™s last known mailing address or local 
equivalent methods). These contact [CONTACT_23526]â€™s 
medical record. 
x Should the patient continue to be unreachab le, he/she will be c onsidered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are addressed in Section 10.1.8. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524804] reasons for screening failure, as applicable. 
The maximum amount of blood collected from each patient over the duration of the study is not 
expected to exceed 650 mL. Repeat or unscheduled samples may be taken for safety reasons or 
for technical issues with the samples. If a patient requires home quarantine due to SARS -CoV-2 infection or exposure, or due to 
COVID-19 symptoms or other associated concern with attending an in-person study visit; home 
health care visits may be conduc ted to continue study assessments  in the patientâ€™s home where 
feasible, and/or remote vis its via telephone, tele medicine, or other appropriate virtual 
communication may be substituted for a visit to the site. 
8.1. Study Assessments 
Planned time points for all safety assessments are provided in the Schedule of Activities.  
8.1.1. Demographics 
Demographic data includes ag e, sex, and race/ethnicity.  
8.1.2. Height and Weight 
Height and weight are collected at Screening and will be used to calculate BMI. Waist 
circumference is also measured at  Screening. Only weight is coll ected on other days specified in 
the Schedule of Activities.  
Waist (abdominal) circumference is measured with measuring-tape position as follows (National 
Heart, Lung, and Blood Institute 2000 ): The upper hip bone and the top of the right iliac crest 
should be located and measuring tape placed in  a horizontal plane around the abdomen at the 
level of the iliac crest. The tape should be snug but should not compress the skin, and should be 
parallel to the floor, at the time of measurement.  The measurement should be taken at the end of 
a normal expi[INVESTIGATOR_1516]. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524805] 2021 
 
 
CONFIDENTIAL  Page 48 of 92  
 8.1.3. Medical History 
Medical and surgical history, including details of illnesses and allergies, date(s) of onset, whether 
condition(s) is currently ongoing, a nd medication history, including al cohol use, will be collected 
for all patients at Screening.  
8.1.4. Physical Examinations 
A complete physical examination will incl ude assessments of general appearance, 
cardiovascular, respi[INVESTIGATOR_696], abdomen, head and ne ck (including ears, eyes, nose, throat, and 
thyroid), lymph nodes, mu sculoskeletal systems, and neurological exam.  
A targeted physical examination may be conducted to evaluate reported current or prior AEs, 
symptoms reported by [CONTACT_102], or  abnormal laboratory readouts.  
Investigators should pay special attention to clinic al signs related to previous serious illnesses. 
8.1.5. Vital Signs 
Temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed and maintained in source documentation.  
Blood pressure and pulse measurements will be assessed with a completely automated device. 
Manual techniques will be used only if an automated device is not available. Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_524806] for the 
patient in a quiet setting without di stractions (e.g., television, cell phones). 
8.1.6. Electrocardiograms 
Single 12-lead ECGs will be obtained as outlined in the Schedule of Activities using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, and QT intervals. QTc will be calculated using the formula outlined in Appendix 4. 
An ad hoc ECG should be performed in the inst ance of patient-reported symptoms considered 
potentially cardiac in nature such as chest pain /pressure, palpi[INVESTIGATOR_814], dizziness, shortness of 
breath, or report of patient recently seeking me dical care for such symptoms (e.g., emergency 
room visit); cardiology consult should be obtai ned based on the clinical judgement of the 
Investigator.  
The Investigator will review the ECGs for any clinically significant abnormalities.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524807] be conducted in 
accordance with the laboratory ma nual and the Schedul e of Activities. 
[IP_ADDRESS]. Liver Function Tests 
In order to be eligible for th is study, patients must have an $/7Â•43 U/L for men or Â• 28 U/L 
for women. ALT and AST stability may be evaluated prior to randomization per Section [ADDRESS_524808] s (LFTs) will be monito red per the Schedule of 
Activities. Refer to Appendix [ADDRESS_524809] of tests to be performed, and to Appendix 3 for 
additional information on criteria for increased liver chemistry monitoring. 
8.1.8. Transient Elastography and Co ntrolled Attenuation Parameter 
Liver stiffness will be assessed by [CONTACT_50407]-controlled transient elastography (via FibroScanÂ®) at 
Screening to determine study eligibility. If re sults from transient elastography measurement 
within [ADDRESS_524810] F1 
fibrosis. The protocol excludes pa tients with cirrhosis based on medical history or clinical signs 
or symptoms (Exclusion criteria #2). Prior studies indicate variability in the ranges of liver 
stiffness measured by [CONTACT_416471]. In 
STELLAR-3, which enrolled patients with bridging fibrosis, median  liver stiffness at baseline 
was approximately 13 kPa, with an interquartile range between 10 and 17 kPa ( Harrison 2020). 
In STELLAR-4, which enrolled patients with cirrhosis, median liver stiffness at baseline was approximately 20-21 kPa, with an interquartile range between 14 and 30 kPa ( Harrison 2020 ). 
The utility of transient elastography to diagnose cirrhosis in the setting of NASH also appears 
limited based on the low positive predictive value (PPV) of even relatively high kPa thresholds. For a threshold of [ADDRESS_524811] udy, the PPV for F4 fibrosis (i.e., cirrhosis) in 
the setting of NASH is 0.37 (which may be even lower in a population with low prevalence of 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524812] 2021 
 
 
CONFIDENTIAL  Page 50 of 92  
 cirrhosis, such as one in which cirrhosis is excluded on clinical grounds), with a negative 
predictive value of 0.96 ( Eddowes 2019 ). This threshold has a sensitivity of 0.59 and a 
specificity of 0.90 for a diagnosis of  cirrhosis in the setting of NASH ( Eddowes 2019 ). 
CAP is an assessment of liver steatosis and is ge nerally used to compleme nt the assessment of 
liver stiffness by [CONTACT_416472] ( Eddowes 2019 ). CAP estimates 
the total ultrasonic attenuation (go-and-return pa th), expressed in dB/m,  based on the postulate 
that fat affects ultrasound propagation. A CAP threshold of 274 dB/m has sensitivity of 0.9 and 
specificity of 0.6 IRULGHQWLILFDWLRQRIOLYHUVWHDWRVLVRIÂ• (Eddowes 2019 ). The threshold of 
280 dB/m was chosen to identify pa tients who are likely to have el evated liver steatosis, in 
conjunction with the other imaging assessments at screening, including cT1. 
Patients who meet NASH entry criteria based on a liver biopsy (Inclusion Criteria #4) should 
still undergo transient elastography at Screening to  enable assessment of change from baseline in 
stiffness by [CONTACT_331436]. Transient elastography will also be  conducted at Week 12, and at ET.  
8.1.9. Magnetic Resonance Imaging: Correct T1 and Proton Density Fat Fraction  
MRI cT1 will be conducted as specified  in the Schedule of Activities.  
MRI cT1 is a novel MRI-based quantitative me tric for assessing a composite of liver 
inflammation and fibrosis. This assessment is based on multiparametric MRI data, measuring 
relaxation time that varies based on extracellular tissue flui d attributed to inflammation and 
fibrosis, with a longer relaxation time occurring w ith more extracellular fluid; the measurement 
is corrected for elevated ir on content, which has an opposi ng effect on relaxation time ( Banerjee 
2014). Values for cT1 have been shown to correl ate with the NAFLD Activity Score (NAS) and 
its components, as well as with de gree of fibrosis by [CONTACT_416473] ( Banerjee 2014; Dennis 
2021). A population at low risk for NAFLD was found to have values ranging from 573 to 852 ms with a median of 666 ms and interqua rtile range from 643 to 694 ms, with high cT1 
values (e.g. > 875 ms) having been shown to stro ngly predict liver-related clinical outcomes 
(e.g., hepatic encephalopathy, varice al bleeding, ascites, death) ( Mojtahed 2019). In conjunction 
with other screening assessments, a threshold of  800 ms will enrich for a NASH population with 
fibrosis; this threshold has a sensitivity of 86% and a specificity of 93% for identifying patients ZLWKÂ•)ILEURVLV Banerjee 2014 ). Stratification for values > [ADDRESS_524813] stability as necessary, per Section 5 .  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524814] 4 weeks of dosing.   
The images will be analyzed by a central reader.  
MRI-PDFF quantifies the relative amount of water vs fat in a tissue bases on signals from proton 
groups that vary depending on tissue cell type ( Caussy 2018 ). PDFF is expressed as a percentage 
(range from 0-100%) representing the ratio of de nsity of mobile protons from triglycerides 
relative to total triglyceride a nd water mobile proton density (a lthough there are also triglyceride 
elements that are not visi ble by [CONTACT_416474]). In the liver, PDFF correlates w ith histological assessment of hepatic steatosis, 
and PDFF has been advanced as a measure of li ver fat content to assess treatment response in 
NASH studies ( Caussy 2018). PDFF values correlate with NA S score on liver histology, with a 
strong correlation with steatosis (rs = 0.68, p < 0.001) ( Dennis 2021 ). A PDFF threshold of Â•
generally reflects abnormal steatosis as seen in NAFLD or NASH (Szczepaniak 2005 ; Tang 
2013). PDFF and cT1 values have been shown to be strongly correlated with each other in 
NASH patients (rs = 0.66, p < 0.001) ( Dennis 2021), but it is not yet established how values with 
these modalities may change in response to an ti-inflammatory therapi[INVESTIGATOR_416450]-201. 
MRI-PDFF data will be collected along with MRI cT1. 
8.2. Pharmacokinetics 
Plasma samples will be collected for measurement of plasma concentra tions of study drug and 
metabolites as specified in the Schedule of Activities and Appendix 2. 
Urine samples will be collected for measuremen t of urine concentrations of study drug and 
metabolites as specified in the Schedule of Activities and Appendix 2.   
Patients in the PK/PD sub-st udy will undergo intensive and tr ough PK sample collection as 
specified in the Schedule of Activities and Appendix 2. 
Patients who are not participating in the PK/PD sub-study will unde rgo trough PK sampling 
only, as specified in the Schedule of Activities and Appendix 2. 
Instructions for the collection and handling of biological samples will be provided by [CONTACT_1034]. The actual date and time  (24-hour clock time) of each  sample will be recorded. 
Samples will be used to evaluate  the PK of study drug and its me tabolites. Samples collected for 
analyses of parent drug and metabolite concentration may also be used to evaluate safety or efficacy aspects related to concer ns arising during or after the study. 
Parent drug and metabo lite concentration information that  may unblind the study will not be 
reported to investigative s ites or blinded personnel until the study has been unblinded. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524815] 2021 
 
 
CONFIDENTIAL  Page 52 of 92  
 In addition, any remaining (left over) samples may be stored a nd used for optional exploratory 
future research on biomarker variants thought to play a role in NASH or to develop methods or 
assays related to the disease process or mech anism of action of the study drug.  Patients must 
provide informed consent for optional explor atory future research as specified in Section 10.1.2. 
8.3. Pharmacodynamics  
Plasma samples will be collected for measurement of VAP-1/SSAO activity and methylamine levels as specified in the Schedule of Activities and Appendix 2.  
Patients in the PK/PD sub-study w ill undergo intensive PD sample collection as specified in the 
Schedule of Activities and Appendix 2.  
Patients who are not participating in the PK /PD sub-study will undergo trough PD sampling only 
as specified in the Schedule of Activities and Appendix 2.   
Instructions for the collection and handling of biological samples will be provided by [CONTACT_429]. The actual date and time  (24-hour clock time) of each sample will be recorded.  
Samples will be used to evaluate the pharmacodynamics of study drug. Samples collected for 
analyses of study drug pharmacodynamics may also  be used to evaluate safety or efficacy 
aspects related to concerns arising during or after the study.  
PD sampling information that may unblind the study will not be reported to investigative sites or 
blinded personnel until the study has been unblinded. In addition, any remaining (left over) samples may be stored a nd used for optional exploratory 
future research on biomarker variants thought to play a role in NASH or to develop methods or 
assays related to the disease process or mech anism of action of the study drug. Patients must 
provide informed consent for optional explor atory future research as specified in Section 10.1.2. 
8.4. Biomarkers 
Collection of samples for biomarke rs related to NASH and inflammation are also part of this 
study. The following samples will be collected from a ll patients in this study as specified in the 
Schedule of Activities:  
x Blood collection for the follo wing NASH/fibrosis biomarke rs: CK-18 (M30 and M65), 
PI[INVESTIGATOR_120861], TIMP-1, HA, PRO-C3, and C3M 
x Blood collection for the following inflammati on biomarkers: hs-CRP, IL-6, ICAM-1, and 
VCAM-1 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524816] 2021 
 
 
CONFIDENTIAL  Page 53 of 92  
 The following exploratory fibrosis scores may also  be calculated: FIB-4, enhanced liver fibrosis 
(ELF), and NAFLD. The PRO-C3/C 3M ratio may be calculated. 
In addition, any remaining (left over) samples may be stored a nd used for optional exploratory 
future research on biomarker variants thought to play a role in NASH or to develop methods or 
assays related to the disease process or mech anism of action of the study drug. Patients must 
provide informed consent for optional explor atory future research as specified in Section 10.1.[ADDRESS_524817] medical o ccurrence that, at any dose, results in the 
following: death; is life threatening; requires in -patient hospi[INVESTIGATOR_059]; results in persistent 
disability or incapacity; is a conge nital anomaly or birth defect; or  is a medically important event 
or reaction that may not be immediately life-threatening or result in death or hospi[INVESTIGATOR_416451].  
Events meeting the definition of an AE or SAE are defined in Appendix 6, including details on 
recording, reporting, and follow-up of AEs and SAEs , assessment of sever ity, and assessment of 
causality. AEs will be reported by [CONTACT_102] (or, when appropriate, by a caregiver, surrogate, or 
the patient's legally authorized re presentative) at every study visit. 
The Investigator and any qualif ied designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study drug or study procedures, or that caused the patient to discontinue the study drug (see Section 7 ). 
8.5.1. Time Period and Frequency for Collecting AE and SAE Information 
After informed consent but prior to initiation of  study drug, the following types of events should 
be reported: all AEs and SAEs related to protocol -mandated procedures.  
Medical occurrences (events considered not relate d to protocol-mandated procedures) that begin 
before the start of study drug but after obtaini ng informed consent will be recorded on the 
Medical History/Current  Medical Conditions section of the eCRF, not the AE section. 
All AEs and SAEs, regardless of cause or relationship, will be collected from the start of study drug through the Follow-Up Period, at every study visit, as specified in the Schedule of 
Activities ( Section 1.3 ). 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524818] 2021 
 
 
CONFIDENTIAL  Page 54 of 92  
 All SAEs will be recorded a nd reported to the Sponsor or designee immediately and under no 
circumstance should this exce ed 24 hours, as indicated in Appendix 6. The Investigator will 
submit any updated SAE data to the Sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek reports of AEs or SAEs after conclusion of the 
study participation. However, if th e Investigator learns of any SAE, including a death, at any 
time after a patient has been discharged from the study, and he/she considers the event to be 
reasonably related to the study dr ug or study participation, the Inve stigator must promptly notify 
the Sponsor. 
8.5.2. Method of Detecting AEs and SAEs 
The method of recording, evaluating, and as sessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 6 . 
Care will be taken not to introduce bias when  detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the patient is the preferred method to inquire about 
AE occurrences. 
8.5.3. Follow-up of AEs and SAEs 
After the initial AE and/or SAE report, the Investigator is required to proactively follow each 
patient at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the 
event is otherwise explained, or the patie nt is lost to follow-up (as defined in Section 7.3 ). 
Further information on follow-up procedures is provided in Appendix 6. 
8.5.4. Regulatory Reporting Requirements for SAEs 
Prompt notification by [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of patients and the safety of a study 
drug under clinical inves tigation can be met. 
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation. The Sponsor 
will comply with country-specific regulatory re quirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and Investigators. 
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwar ded to Investigators as necessary. 
An Investigator who receives an investigator sa fety report describing a SAE or other specific 
safety information (e.g., summary or  listing of SAEs) from the sponsor  will review and then file 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524819] 2021 
 
 
CONFIDENTIAL  Page 55 of 92  
 it along with the Investigatorâ€™s Brochure and will no tify the IRB/IEC, if appropriate according to 
local requirements. 
8.5.5. Pregnancy 
Details of all pregnancies in female patients and female partners of male patients will be 
collected after the start of study drug until [ADDRESS_524820] dose of the study drug. 
If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 6 and 
Appendix 7. 
Abnormal pregnancy outcomes (e .g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs. 
8.6. Treatment of Overdose 
Overdose with this product has not been reported. Neither the effect of overdose nor antidote are 
known. The maximum amount of TERN-[ADDRESS_524821] single dose of  TERN-201 capsules in clinical studies was 
10 mg. Patients who receive higher than the protocol-defined dose should be carefully monitored 
for adverse events, and the quantity of the ex cess dose and duration of excess dose should be 
documented in the eCRF; the Medical Monitor should be notified immediately. Refer to Appendix 6 for additional information on AE reporting.  
In an instance in which a patient receives higher than the protocol-defined dose, decisions 
regarding any future dosing of study drug will be made by [CONTACT_416475]. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524822] 2021 
 
 
CONFIDENTIAL  Page 56 of 92  
 9. Statistical Considerations 
9.1. Statistical Hypotheses 
The primary objective of the study is to evaluate the safety and tolerability of orally administered 
TERN-201. No statistical hypothesis testing will be applied. 
9.2. Sample Size Determination 
The sample size is based on clinical feasibility and adequate size to characterize safety in the study population, without consider ation for statistical power.   
Patients who are randomized but do not receiv e study drug for any reason may be replaced. 
Patients who discontinue treatment early for reasons other than safety (e.g., withdrawal of 
consent, lost to follow-up, patient relocated) ma y also be replaced. Re placement patients will 
receive the same treatment assignment as the patient that discontinued treatment early.   
9.3. Analysis Sets 
The following analysis sets are defined: 
Analysis Sets Description 
Randomized All patients who are ra ndomized into any one of the 
treatment groups 
PK All randomized patients who received at least [ADDRESS_524823] 1 dose of study 
drug (TERN-201 or placebo) and have evaluable PD data 
Safety All patients w ho received at least [ADDRESS_524824] 1 dose of study 
drug. Patients will be analyzed according to the intervention they are planned to receive.  
Per Protocol Analysis Set ( PP)  All randomized patients who have completed the study 
without any major protocol de viations. The major protocol 
deviations will be defined in the Statistical Analysis Plan (SAP) and finalized prior to data base lock (DBL). A separate 
completer analysis set may also  be defined in the SAP.  
 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524825] completed the study if he/she has completed a ll phases of the 
study including the last scheduled assessment in the Follow-Up Period. 
9.4. Statistical Analyses 
This section presents a summary of the planned statistical analyses. The SAP will provide the 
details and will be finalized prior to clinical database lock.  
9.4.1. General Considerations 
For continuous data, summary statistics will include the arithme tic mean, arithme tic standard 
deviation, median, minimu m, maximum, and number of patie nts with non-missing assessments. 
For log-normal data (e.g., the PK parameters: AUCs and ma ximum observed concentration 
[Cmax]), the geometric mean and coefficient of variation (CV%) will also be presented. For 
categorical data, frequency counts and percentages will be presented.   
9.4.2. Primary Endpoint(s) 
The primary safety parameters will include TEAEs and treatment emergent clinical safety 
laboratory parameters.  
Reported AEs will be coded using the latest version of Medical Dictionary for Regulatory 
Activities (MedDRA) and graded for sever ity according to NCI CTCAE, Version 5.0.  
All TEAEs will be listed and incidence summarized by [CONTACT_416476], as well as by [CONTACT_416477]. Summaries of treatment 
emergent SAEs, TEAEs relate d to study drug, TEAEs resulting in study drug discontinuations, 
and deaths will also be produced. 
Changes and percent changes from baseline of quantitative measurements will be summarized by 
[CONTACT_416478]. Laboratory abnormalitie s will be graded according to NCI 
CTCAE Version 5.0, where applicable. Shifts in CTCAE grade from baseline will be summarized by [CONTACT_1570].  
Further details on the analysis of additional safety parameters will be provided in the SAP. 
9.4.3. Secondary Endpoints 
[IP_ADDRESS]. Pharmacokinetic Endpoints 
Noncompartmental PK analysis will be performed on individual plasma and urine concentration 
data. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524826] 2021 
 
 
CONFIDENTIAL  Page 58 of 92  
 Individual plasma concentrations  of TERN-201 and its metabolites, if applicable, will be listed 
by [CONTACT_416479]. Individual a nd mean concentration-time 
profiles will be presented graphically in linear and semi-log scales.  
PK parameters of TERN-201 a nd its metabolites (explorator y endpoint) will be listed 
individually and summarized with descriptive statistics, including arithmetic and geometric 
mean, median, standard devia tion, arithmetic and geometric CV %, minimum and maximum. The 
Cmax and AUC will be plotted. 
[IP_ADDRESS]. Change from Baseline in Pl asma VAP-1/SSAO Activity 
A secondary efficacy endpoint is change from baseline in plasma VAP-1/SSAO activity with 12 
weeks of treatment in patients treated with either TERN-201 or matching placebo. The change 
and percent change from baseline in plasma VAP-1/SSAO amine oxidase activity in each TERN-[ADDRESS_524827] baseline visit, without 
controlling for any family-wise error rate (overall type I error), using MMRM (mixed model repeated measures) model with treatment group, vi sit, and treatment group by [CONTACT_416480]. 
Change and percent change from baseline plasma VAP-1/SSAO amine oxidase activity will be 
listed and summarized with descriptive statistics including arithmetic and geometric mean, median, standard deviation, ar ithmetic and geometric CV, minimum, and maximum. Exposure-
response and dose-response relations hips of orally administered TERN-201 will also be assessed 
as applicable (exploratory endpoints). 
Exposure-response and dose-response analysis may be  produced if Part 2 of the study is enrolled, 
as applicable. The change and percent change  from baseline in plasma VAP-1/SSAO activity 
will be compared between the different TERN-201 dose groups and placebo using an analysis of 
covariance (ANCOVA) model with the treatment group as a factor and baseline values as a 
covariate. Corresponding least square mean treatment differences with 2 sided 95% confidence 
limits will be computed for each pairwise comparison.  
Further details on the analysis models will be provided in the SAP. 9.4.4. Exploratory Endpoints 
Descriptive statistics for the values, change from baseline, and percent change from baseline will 
be summarized by [CONTACT_51250].  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524828] 2021 
 
 
CONFIDENTIAL  Page 59 of 92  
 The following exploratory endpoints will be analyzed at each visit using an MMRM model 
similar to the model described in Section [IP_ADDRESS]. Exposure-response and dose-response analysis 
may be produced if Part [ADDRESS_524829] 
x Change from baseline in NASH and fibrosis biomarkers 
x Change from baseline in in flammatory biomarkers 
x Change from baseline in eGFR, urine protein, UPCR, and UACR  
x Change from baseline in plasma methylamine levels (PD marker of VAP-1/SSAO 
inhibition) 
[IP_ADDRESS]. PD Endpoints 
In addition to analyses described above, pharmacodynamic paramete rs (plasma VAP-1/SSAO 
activity and plasma methylamine levels) will be listed, summarized, and described by [CONTACT_416481]-time curve or time-effect curve. The correlation of PK and PD parameters will also be explored.  
9.5. Interim Analysis 
An interim analysis will be performed after all patients in Part [ADDRESS_524830] completed Week 6 assessments. Interim PD data will be assessed as described in Section [IP_ADDRESS]. If robust VAP-1/SSAO activity suppression is obs erved and available PK suggest s that a lower dose may also 
possibly lead to robust VAP-1/SSAO activity su ppression, enrollment in Part 2 with 4 mg 
TERN-201 may be initiated. Additionally, if safety  data indicates 10 mg TERN-201 is overall 
safe and well-tolerated and anticipated exposures with a higher dose remain below the exposure limit (see  Section 4.3 ), enrollment in Part 2 to assess a dose up to 20 mg TERN-201 in Part 2 
may be initiated. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524831] 2021 
 
 
CONFIDENTIAL  Page 60 of 92  
 Additionally, an administrative interim analysis ma y be conducted after the completion of Part 1 
of the study and will be  detailed in the SAP.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524832] 2021 
 
 
CONFIDENTIAL  Page 61 of 92  
 10. Regulatory, Ethical, and Study Oversight Considerations  
10.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
x Consensus ethical principles  derived from international guidelines including the 
Declaration of Helsinki and Council for Intern ational Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines 
x Applicable International Council for Ha rmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines 
x Applicable laws and regulations 
The protocol, protocol amendments, ICF, Invest igator Brochure, and ot her relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_78792]/IEC befo re the study is initiated. 
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study patients. 
The Investigator will be responsible for the following: 
x Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirement s, policies, and proc edures established by 
[CONTACT_1201]/IEC 
x Notifying the IRB/IEC of SAEs or other si gnificant safety findings as required by 
[CONTACT_1744]/IEC procedures 
x Providing oversight of the conduct of the study at the site and adhe rence to requirements 
of 21 Code of Federal Regul ations (CFR), ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other app licable local 
regulations 
10.1.1. Financial Disclosure 
Investigators and Sub-Investigat ors will provide the sponsor with  sufficient, accurate financial 
information as requested to allow the sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing informa tion on financial intere sts during the course of the study and for 
1 year after completion of the study. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524833] 2021 
 
 
CONFIDENTIAL  Page 62 of 92  
 10.1.2. Informed Consent Process 
The Investigator or his/her representative will explain the nature of the study to the patient or 
his/her legally authorized representative a nd answer all questions regarding the study. 
Patients must be informed that their participation is voluntary. Patients or their legally authorized representative will be required to sign a statement of informed consent that meets the requirements of [ADDRESS_524834] (HIPAA) requirements, where applicable, and the IRB/IEC or study center. 
The medical record must include a statement that written informed consent was obtained before the patient was enrolled in the study and the date the written consen t was obtained. The 
authorized person obtaining the informed consent must also sign the ICF. 
Patients must be re-consen ted to the most current version of the ICF(s) during their participation 
in the study. 
A copy of the ICF(s) must be provided to the patient or the patientâ€™s  legally authorized 
representative. The ICF will contain a separate section that addresses the use of remaining mandatory samples 
for optional exploratory research for up to 15 years after the end of the study. The Investigator or authorized designee will explain to each patient  the objectives of the exploratory research. 
Patients will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period. A separate signature  [CONTACT_33509] a patient's agreement to allow any rema ining specimens to be used for exploratory 
research. Patients who decline to participate in this optional research will not provide this separate signature. 
Written informed consent may be obtained via te lephone with appropriat e documentation of how 
the informed consent form was transmitted to the patient, (such as via email, fax, or mail) and 
how signature [CONTACT_416491]. Screen ing may be initiated via telephone to avoid a visit to the site 
if the patient is disqualif ied based on medical history. 
10.1.3. Data Protection 
Patients will be assi gned a unique identifier by [CONTACT_456]. A ny patient records or  datasets that 
are transferred to the sponsor will contain the identifier only; patient names or any information which would make the patient identifiable will not be transferred. 
The patient must be informed that his/her pers onal study-related data will be used by [CONTACT_135711]. The le vel of disclosure must also be explained to 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524835] be informed that his/her medical records may be examined by [CONTACT_416482], by [CONTACT_99473]/IEC members, and by [CONTACT_6668]. 
10.1.4. Dissemination of Clinical Study Data 
A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies) by 
[CONTACT_416483], as appropriate. Terns will ensure that the report meets the standards set out in the ICH 
Guideline for Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in certain cases. Public disclo sure of study results will be in 
accordance with all applicable laws and IC H guidelines. The posting of company-sponsored 
study information and tabular st udy results may be presented on the US National Institutes of 
Healthâ€™s website  www.ClinicalTrials.gov  and other publicly accessible sites. 
10.1.5. Data Quality Assurance 
All patient data relating to the study will be recorded  on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_112247]. 
The Investigator must maintain accurate do cumentation (source data) that supports the 
information entered in the eCRF. The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide dir ect access to source data documents. 
Monitoring details describing stra tegy (e.g., risk-based initiatives in operations and quality such 
as Risk Management and Mitiga tion Strategies and Analytical Risk-Based Monitoring), methods, 
responsibilities and require ments, including handling of noncom pliance issues and monitoring 
techniques (central, remote, or on- site monitoring) are available in  the Monitoring Plan and site-
specific contracts.  
The sponsor or designee is responsible for the data management of th is study including quality 
checking of the data. The sponsor assumes accountability for actions de legated to other indi viduals (e.g., Contract 
Research Organizations). 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524836] 2021 
 
 
CONFIDENTIAL  Page 64 of 92  
 Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and ri ghts of patients are being protect ed; and that the study is being 
conducted in accordance with the currently appr oved protocol and any other study agreements, 
ICH GCP, and all applicable  regulatory requirements. 
Records and documents, including signed ICFs, pe rtaining to the conduct of this study must be 
retained by [CONTACT_31201] [ADDRESS_524837] approval of a marketing application in an ICH region (i.e., [LOCATION_002], Europe, or Japan) and until there are no pending or contemplated marketing applications in an ICH region (i.e., [LOCATION_002], Europe, or Japan) or 
at least [ADDRESS_524838]. These doc uments should be retained for a longer period however if 
required by [CONTACT_8146](s) or if needed by [CONTACT_456]. No records may be destroyed during the retenti on period without the written approv al of the sponsor. No records 
may be transferred to another location or party without written notification to the sponsor. 
10.1.6. Protocol Deviations 
Prospective approval of protocol  deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. In the event of a significant deviation related to 
gross non-compliance from the protocol, or events that impose significant risk to patient safety, 
the Investigator or designee must notify the S ponsor or designee immediat ely. Deviations must 
be documented in accordance with the Sponsorâ€™s procedures, and in accordance with any site 
procedures or processes.  
10.1.7. Source Documents 
Source documents provide evidence for the existen ce of the patient and substantiate the integrity 
of the data collected. Source documents are stored at the Investigatorâ€™s site. 
Data reported on the eCRF or entered in the e CRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies mu st be explained. The 
Investigator may need to request previous medi cal records or transfer records, depending on the 
study.  The required source data should include notes c ontaining at least the following information for 
each patient:  
x Patient identification (name,  date of birth, gender) 
x Documentation that the patient meets eligibility criteria 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524839] 2021 
 
 
CONFIDENTIAL  Page 65 of 92  
 x Documentation of the reason(s) a consented patient is not enrolled 
x Participation in study (including study number) 
x Study discussed and date of informed consent 
x Dates of all visits 
x Documentation that protocol specific procedures were performed 
x Results of efficacy parameters , as required by [CONTACT_760] 
x Start and end date (i ncluding dose regimen) of study drug administration, including dates 
of dispensation and return as applicable 
x Record of all adverse events and other sa fety parameters (sta rt and end date, and 
including causality and severity) 
x Concomitant medication (including start and end date, dose if relevant; dose changes) 
x Date of study completion and reason for early discontinuation, if applicable  
10.1.8. Study and Site Start and Closure 
The first patient screened is considered the fi rst act of recruitment a nd will be the study start 
date. 
The sponsor or designee reserves the right to cl ose the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required docu ments and study supplies 
have been collected and a study-site  closure visit has been performed. 
The Investigator may initiate study-site closure at any time, pr ovided there is reasonable cause 
and sufficient notice is given in a dvance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_3433] e sponsor or Investigator may include but are 
not limited to: 
x Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the spons or's procedures, or GCP guidelines 
x Inadequate recruitment of patients by [CONTACT_737] 
x Discontinuation of further study drug development 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524840] 2021 
 
 
CONFIDENTIAL  Page 66 of 92  
 organization(s) used in the study of the reason fo r termination or suspension, as specified by [CONTACT_13179]. The Investig ator shall promptly inform the patient and 
should assure appropriate follow-up care as warran ted by [CONTACT_416484]. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524841] 2021 
 
 
CONFIDENTIAL  Page 67 of 92  
 Appendix 1: Clinical Laboratory Tests 
The tests detailed in Table [ADDRESS_524842] be entered into the 
eCRF. 
Protocol-specific requirements for inclusion or exclusion of patients are detailed in Section 5 . 
Additional tests may be performed at any time during the study as  determined necessary by [CONTACT_56861]. Table 2 Protocol-Required Clin ical Laboratory Assessments 
Laboratory 
Assessments Parameters 
Hematology Hematocrit 
Hemoglobin 
Hemoglobin A1c1 
Platelet Count RBC Count RBC Indices:  
x MCV 
x MCH 
x MCHC 
x % Reticulocytes WBC count with Differential: 
x Neutrophils 
x Lymphocytes 
x Monocytes 
x Eosinophils 
x Basophils 
Clinical 
Chemistry2 Bicarbonate 
BUN Calcium Chloride CPK Creatinine eGFR
3 
Glucose  Phosphorus  Potassium Sodium Liver Function Tests:  
x ALT 
x Albumin 
x AST 
x ALP 
x GGT 
x Total and Direct Bilirubin
4 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524843] 2021 
 
 
CONFIDENTIAL  Page 68 of 92  
 Laboratory 
Assessments Parameters 
Total Protein 
Coagulation5 aPTT1 
PT/INR  
Fasting Lipid 
Profile HDL 
LDL Total Cholesterol Triglycerides  VLDL 
Urinalysis x Specific gravity 
x pH, glucose, protein, albumin, cr eatinine, blood, ketones, bilirubin, 
urobilinogen, nitrite, leukocyte este rase by [CONTACT_5230], UPCR, and UACR 
x Microscopic examination (if bl ood or protein is abnormal) 
Pregnancy  Highly sensitive s HUXPÈ• -hCG (WOCBP only) 
Other Tests x FSH (to confirm post-menopausal status)1 
x Blood alcohol test1 
x Urine drug screen including amphe tamines, barbiturates, cocaine, 
opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651] 
x Serology1: HIV antibody, HBsAg, and HCV antibody6 
x COVID-19: SARS-CoV-[ADDRESS_524844] for active infection (e.g., molecular test 
such as PCR or viral antigen serol ogy), and SARS-CoV-[ADDRESS_524845] (IgG 
and IgM) 
NOTES: 
1 Only collected at Screening. 
2 Details of liver chemistry increased monitoring criteria are given in Appendix 3.  
3 eGFR to be calculated by [CONTACT_35970]; refer to  Appendix [ADDRESS_524846].  
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine tran saminase; AST = aspartate transaminase; aPTT = 
activated partial thromboplastin time; È•-K&* È• -human chorionic gonadotropin; BUN = blood urea nitrogen; 
CPK = creatine phosphokinase; eGFR = estimated glomerul ar filtration rate; FSH = Follicle-stimulating hormone 
GGT = gamma-glutamyl transpeptidase; HbA1c = hemoglobin A1c; HBsAg = hepatitis B surface antigen; HCG = 
human chorionic gonadotropin; HCV = hepatitis C virus; HDL = high-density lipoprotein; HIV = human 
immunodeficiency virus; IgG = immunoglobulin G; IgM = immunoglobulin M; INR = international normalized 
ratio; LDL = low-density lipoprotein; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; PCR = polymerase chain reaction; PT = 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524847] 2021 
 
 
CONFIDENTIAL  Page 69 of 92  
 prothrombin time; RBC = red blood cell; RNA = ribonucleic acid; SARS-CoV-2 = Severe Acute Respi[INVESTIGATOR_81370] 2; UACR = urine albumin:creatinine ratio; UPCR = urine protein:creatinine ratio; VLDL 
= very low-density lipoprotein ; WBC = white blood cell; WOCBP = women of childbearing potential 
Investigators must document their review of each  laboratory safety report . Clinically significant 
laboratory shifts, or a ny clinically significant abnormalities considered possibly related to study 
drug in the opi[INVESTIGATOR_689], should be repeated within 48- 72 hours and followed to 
resolution or until stable.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524848] 2021 
 
 
CONFIDENTIAL  Page 70 of 92  
 Appendix 2: Sample Collection for Pharmacokinetics and Pharmacodynamics  
Table 3  presents a description of PK/PD sample re quirements at each study visit and timepoint. 
Table 3 PK/PD Sampling Timepoints  
Week Day Timepoint  
01 1 x Pre-dose (All Patients) 
x Post dose at the following timepoints (PK/PD sub-study only): 
o 30 Â± 2 minutes 
o 1 hour Â± 5 minutes 
o 2 hours Â± 5 minutes 
o 4 hours Â± 15 minutes 
o 6 hours Â± 15 minutes 
o 8 hours Â± [ADDRESS_524849] dose (PK/PD sub-study 
only) 
[ADDRESS_524850] Day 1 dose at the follo wing timepoint (PK/PD sub-study 
only): 
o 24 hours Â± 1 hour 
2 15 Â± 3 x Pre-dose (All Patients) 
4 29 Â± 3 x Pre-dose (All Patients) 
6 43 Â± 3 x Pre-dose (All Patients) 
x Post dose at the following timepoints (PK/PD sub-study only): 
o 30 Â± 2 minutes 
o 1 hour Â± 5 minutes 
o 2 hours Â± 5 minutes 
o 4 hours Â± 15 minutes 
o 6 hours Â± 15 minutes 
o 8 hours Â± [ADDRESS_524851] dose (PK/PD sub-study 
only) 
[ADDRESS_524852] Week 6 dose at the following timepoint (PK/PD sub-study 
only): 
o 24 hours Â± 1 hour 
8 57 Â± 3 x Pre-dose (All Patients) 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524853] 2021 
 
 
CONFIDENTIAL  Page 71 of 92  
 Week Day Timepoint  
12 85 Â± 3 x Pre-dose (All Patients) 
x Post dose at the following timepoints (PK/PD sub-study only): 
o 30 Â± 2 minutes 
o 1 hour Â± 5 minutes 
o 2 hours Â± 5 minutes 
o 4 hours Â± 15 minutes 
o 6 hours Â± 15 minutes 
o 8 hours Â± [ADDRESS_524854] Week 12 dose at the following timepoint (PK/PD sub-study 
only): 
o 24 hours Â± [ADDRESS_524855] Week 12 dose at the following timepoint (PK/PD sub-study 
only): 
o 48 hours Â± [ADDRESS_524856] Week 12 dose at the following timepoint (PK/PD sub-study 
only): 
o 72 hours Â± 4 hours 
ET ET x At the ET Visit, for all patients discontinuing the study at any time 
for any reason prior to Week 12 
NOTES:  
1 sVAP-1 will be collected along with PD  sampling at Week 0/Day 1 pre-dose.   
Abbreviations:  ET = early termination; PD = pharmacodynamics; PK = pharmacokinetics; sVAP-1 = soluble 
vascular adhesion protein-1   
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524857] 2021 
 
 
CONFIDENTIAL  Page 72 of 92  
 Appendix 3: Liver Chemistry Increased Monitoring Criteria 
Table [ADDRESS_524858] abnormalities. 
Table 4 Liver Chemistry Increased Monitoring Criterion and Follow-Up 
Criterion Actions 
Elevated ALT and/or AST above 2 Ã— 
Baseline or above 5 Ã— ULN for < 1 week x Patient can continue stud y drug at the discretion 
of the Investigator 
x Repeat measurement of LFTs (including ALT, 
AST, ALP, and total bilirubin) will be performed within 48-[ADDRESS_524859] bilirubin.  
x PT/INR and albumin will be tested when significantly abnormal liver  function is observed, 
and repeated with repeat measurement of LFTs. 
x Upon confirmation of elevated LFTs, close 
observation by [CONTACT_416485] 24 to 72 
hours will be initiate d immediately.  
x Frequency of monitoring can be decreased as LFTs decrease at the Investigatorâ€™s discretion.  
x The Investigator will collect detailed history information on concomitant symptoms, new medications, drug or alcohol exposure, etc., to identify possible cause of abnormal LFTs.  
x Close observation on abnormal LFTs will last until the parameters return to baseline, or to a stable level judged by [CONTACT_737].   
Note: If one of the following situations occurs and is considered related to the study drug without 
alternative etiology, study drug may be discontinued at the discretion of the Investigator and the 
Medical Monitor should be informed (with repeat test performed within 48-72 hours once initial 
abnormality is detected):  
x ALT or AST > 8 Ã— ULN  
x ALT or AST > 5 Ã— ULN for more than [ADDRESS_524860] > 2Ã— Baseline with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (> 5%) 
x ALT or AST > 2 Ã— Baseline and total bilirubin > 2 Ã— ULN or INR >1.5 for more than 1 week, 
confirmed with a repeat assessment 
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine tr ansaminase; AST = aspartate transaminase; INR = 
international normalized ratio; LFT = liver function test; PT = prothrombin time; ULN = upper limit of normal  
  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524861] 2021 
 
 
CONFIDENTIAL  Page 73 of 92  
 Appendix 4: Fridericiaâ€™s Formula 
A single 12-lead ECG will be obtained as outlined in the Schedule of Activities (see  Section 1.3) 
using an ECG machine that automatically calculates the heart rate and measures PR, QRS, and 
QT intervals. QTc will be calculated using Fridericiaâ€™s Formula as outlined below.  
The Investigator will review the ECGs for any clinically significant abnormalities.  
Fridericiaâ€™s Formula:  
QTcF = QT/(RR^0.33) 
http://www.thecalculator.co/health/QTc-Calculator-385.html  
  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524862] 2021 
 
 
CONFIDENTIAL  Page 74 of 92  
 Appendix 5: Chronic Kidney Disease Epi[INVESTIGATOR_10444] (CKD-EPI) 
Formula to Estimate Glomerular Filtration Rate  
 
GFR = 141 Ã— min(S crÈ›Ä® Ã— max(S crÈ›-1.209 Ã— 0.993Age Ã— 1.018 [if female] Ã— 1.159 [if black] 
 
Abbreviations / Units:  
SCr (standardized serum creatinine) = mg/dL 
È› IHPDOHVRUPDOHV  
Ä® -0.329 (females) or -0.411 (males) 
PLQ LQGLFDWHVWKHPLQLPXPRI6&UÈ›RU  
PD[ LQGLFDWHVWKHPD[LPXPRI6&UÈ›  or 1 
age = years  
  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524863] 2021 
 
 
CONFIDENTIAL  Page 75 of 92  
 Appendix 6: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting 
AE Definition 
x An AE is any untoward medical occurrence in a patient or c linical study patient, 
temporally associated with the use of study drug, whether or not c onsidered related to 
the study drug. 
x NOTE: An AE can therefore be any unfa vorable and unintended sign (including an 
abnormal laboratory finding), sy mptom, or disease (new or exacerbated) temporally 
associated with the use of study drug. 
 
Events Meeting the AE Definition 
x Any safety assessment (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical and scientific judgment of the Investigator (i.e., not  related to progression of 
underlying disease). 
x A clinical condition or symptom associated  with an abnormal la boratory test result 
(e.g., hematology, clinical chemistry, or urinalysis). An a bnormal laboratory test that is 
not accompanied with other signs or sympto ms should not be reported as an AE.  
x Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or severity of the condition. 
x New conditions detected or diagnosed af ter study drug administration even though it 
may have been present before the start of the study. 
x Signs, symptoms, or the clinical sequela e of a suspected drug-drug interaction. 
x Signs, symptoms, or the clinical sequelae of  a suspected overdose of either study drug 
or a concomitant medication. Overdose per se  will not be reported as an AE/SAE 
unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be repor ted regardless of sequelae. 
 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524864] 2021 
 
 
CONFIDENTIAL  Page 76 of 92  
 Events NOT Meeting the AE Definition 
x Abnormal laboratory findings or  other abnormal safety assessm ents that are associated 
with an underlying disease present at base line without worsening, unless judged by [CONTACT_113544]â€™s condition. 
x An abnormal laboratory test that is not accompanied with other signs or symptoms. 
x The disease/disorder being studied or signs, or symptoms of the disease/disorder being 
studied, unless more severe than expected for the patientâ€™s condition. 
x Medical or surgical procedure (e.g., e ndoscopy, appendectomy): the condition that 
leads to the procedure is the AE. 
x Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]). 
x Anticipated day-to-day fluctuations of pre-ex isting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
Definition of SAE 
An SAE is an AE that meets the following criteria: 
An SAE is defined as any untoward me dical occurrence that, at any dose: 
a. Results in death 
b. Is life-threatening 
The term 'life-threatening' in the definition of 'serious' refers to an event in which the patient 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if  it were more severe. 
c. Requires inpatient hospi[INVESTIGATOR_32957] 
x In general, hospi[INVESTIGATOR_329887] (usually 
involving at least an overnight  stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been appropriate in the physicianâ€™s office or 
outpatient setting. Complications that o ccur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_377327], the event is 
serious. When in doubt as to whether â€œhosp italizationâ€ occurred or was necessary, the 
AE should be considered serious. 
x Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen 
from baseline is not considered an AE. 
d. Results in persistent disability/incapacity 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524865] 2021 
 
 
CONFIDENTIAL  Page 77 of 92  
 x The term disability means a substantial disruption of a personâ€™s ability to conduct 
normal life functions. 
x This definition is not intended to include  experiences of relatively minor medical 
significance such as uncompli cated headache, nausea, vo miting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankl e) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Other situations: 
x Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situa tions such as important medical events that may not be 
immediately life-threatening or result in death or hospi[INVESTIGATOR_416452]. Thes e events should usually be considered 
serious. 
x Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for alle rgic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of  drug dependency or 
drug abuse.  
If an event does not meet the AE definition, then it cannot be an SAE even if serious conditions 
are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease). 
Recording and Follow-Up of an AE and/or SAE 
AE and SAE Recording 
x When an AE and/or SAE occurs, it is the res ponsibility of the Investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_416453], laboratory re ports, and diagnostics 
reports) related to the event. 
x The Investigator will then record all relevant AE and/or SAE information in the eCRF. 
x It is not  acceptable for the Investigator to send photocopi[INVESTIGATOR_113502]â€™s medical 
records to the Sponsor or designee in lie u of completion of the AE or SAE eCRF. 
x There may be instances when copi[INVESTIGATOR_416454]. In this case, all patient identifiers, with the exception of 
the patient number, will be redacted on the copi[INVESTIGATOR_113504]. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524866] 2021 
 
 
CONFIDENTIAL  Page 78 of 92  
 x The Investigator will attempt to establis h a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE and/or SAE. 
Assessment of Severity  
The Investigator will be asked to provide an assessment of the severity of the AE using NCI 
CTCAE v5.0 categories as follows:  
x Grade 1: Mild; asymptomatic or mild sympto ms; clinical or dia gnostic observations 
only; intervention not indicated.  
x Grade 2: Moderate; minimal, local, or noni nvasive intervention indicated; limiting age 
appropriate instrumental ADL.  
x Grade 3: Severe or medically significan t but not immediately life-threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self-
care ADL.  
x Grade 4: Life-threatening consequenc es; urgent intervention indicated.  
x Grade 5: Death related to AE. 
For detailed organ system AE severity grading, please refer to NCI CTCAE v5.0:  
https://ctep.cancer.gov/protocoldevelopment/electronic_ applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf  
 
Assessment of Causality 
x The Investigator is obligated to assess the relationship between study drug and each 
occurrence of each AE and/or SAE. 
x The Investigator (or designee) will make a determination of the relationship of the AE to the study drug using a 4-category system  according to the following guidelines:  
o Not Related: The AE is definitely caused by [CONTACT_423]â€™s clinical state or the study procedure/conditions.  
o Unlikely Related:  The temporal association between the AE and the drug is 
such that the drug is not likely to have any reasonable association with the AE.  
o Possibly Related:  The AE follows a reasonable temporal sequence from the 
time of drug administrati on but could have been produced by [CONTACT_423]â€™s 
clinical state or the study procedures/conditions.  
o Related:  The AE follows a reasonable temporal sequence from administration 
of the drug, abates upon discontinuation of the drug, follows a known or hypothesized cause effect relationship, a nd (if appropriate) reappears when the 
drug is reintroduced. 
x For each AE and/or SAE, the Investigator must  document in the medical notes that 
he/she has reviewed the AE and/or SAE and has provided an assessment of causality. 
x There may be situations in which an SA E has occurred and the Investigator has 
minimal information to include in the in itial report to the Sponsor or designee. 
However, it is very important that the I nvestigator always make an assessment of 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524867] 2021 
 
 
CONFIDENTIAL  Page 79 of 92  
 causality for every event before the initial tr ansmission of the SAE data to the Sponsor 
or designee. 
x The Investigator may change his/her opi[INVESTIGATOR_9242]-up 
information and send a SAE follow-up report  with the updated ca usality assessment. 
x The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
Follow-up of AEs and SAEs 
x The Investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medi cally indicated or as requested by [CONTACT_416486] a nd/or causality of the AE or SAE as fully 
as possible. This may include additiona l laboratory tests or  investigations, 
histopathological examinations, or consultation with other health care professionals. 
x If a patient dies during participation in  the study or during a recognized follow-up 
period, the Investigator will provide the Sponsor or designee with a copy of any post-mortem findings including histopathology.  
x New or updated information will be recorded in the originally completed CRF. 
x The Investigator will submit a ny updated SAE data to the Sponsor or designee within 
24 hours of receipt of the information.  
Reporting of SAEs 
SAE Reporting to Sponsor or designee via Paper CRF 
x Email transmission of the SAE paper Report Form is the preferred method to transmit this information to the CATO Safety Group ( [EMAIL_7953] ). 
x Notification by [CONTACT_416487] e CATO Safety Group is also acceptable 
([PHONE_8639]) 
x Initial notification via telephone or email does not replace the need for the Investigator 
to complete, sign, and return the SAE report form within the designated reporting time 
frames. 
x Contacts and additional instructions for SA E reporting can be found in in the Study 
Procedures Manual provided.  
  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524868] 2021 
 
 
CONFIDENTIAL  Page 80 of 92  
 Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information 
Definitions: 
Woman of Childbearin g Potential (WOCBP)  
A woman is considered fertile following mena rche and until becoming post-menopausal unless 
permanently sterile (see below).  Women in the following categories are not considered WOCBP 1. Premenopausal female with surgical sterility defined as 1 of the following: 
x Documented hysterectomy 
x Documented bilateral salpi[INVESTIGATOR_1656] 
x Documented bilateral oophorectomy 
 
2. Postmenopausal female 
x A postmenopausal state is defined as no mens es for 12 months without an alternative 
medical cause. 
o A high follicle stimulating hormone (FSH) level in the postmenopausal range should 
be used to confirm a postmenopausal  state in women not using hormonal 
contraception or hormonal replacement therapy (HRT).  
x Females on HRT and whose menopausal status is in doubt will be required to follow the 
protocol-mandated contraception guidance if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirma tion of postmenopausal 
status before study enrollment. 
For individuals with permanent infertility due to an alternate medical cause not listed above, 
(e.g., mullerian agenesis, androgen insensitivity), Investigator discretion should be applied to 
determining study entry.  
Note: Documentation can come from the site personnelâ€™s: review of the patientâ€™s medical 
records, medical examination, or  medical history interview. 
Contraception Guidance: 
Male patients who are sexually active with a female partner of childbearing potential must be 
either surgically sterile (confirmed by [CONTACT_416488] > 90 days af ter the procedure) or 
follow the guidance per Table [ADDRESS_524869] dose of the study drug. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524870] either be 
surgically sterile (documented hysterectomy, bilateral salpi[INVESTIGATOR_1656], bilateral oophorectomy) or 
follow the guidance per Table [ADDRESS_524871] dose of the 
study drug.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524872] 2021 
 
 
CONFIDENTIAL  Page 82 of 92  
 Table 5 Contraceptive Methods  
CONTRACEPTIVE METHODS ALLOWED DURING THE STUDY INCLUDE:  
A. Highly Effective Methods That Have Low User Dependency and May be Used Alone  
Failure rate of <1% per year when used consistently and correctly. 
x Documented bilateral tubal occlusion  
x Vasectomized partner 
Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual 
partner of the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception sh ould be used. Spermatogenesis cycle is approximately 
[ADDRESS_524873] be Used in Combination with a Barrier Method Failure rate of 
<1% per year when used consistently and correctly.  
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation 
 oral 
 intravaginal 
 transdermal 
 injectable 
Male condoms must be used in addition to hormonal cont raception. Hormonal contracept ion must be at a stable 
GRVHIRUÂ•PRQWKVSULRUWRUDQGRPL]DWLRQ  
Progestogen-only hormone contraception associated with inhibition of ovulation 
 oral 
 injectable 
Male condoms must be used in addition to hormonal cont raception. Hormonal contracept ion must be at a stable 
GRVHIRUÂ•PRQWKVSULRUWRUDQGRPL]DWLRQ  
Implantable progestogen-only hormone contraception associated with inhibition of ovulation 
Intrauterine device (IUD) 
Intrauterine hormone-releasing system (IUS)  
C. Barrier Methods That Must be Used in Combination with a Highly Effective Method (B, above) 
Male condom with or without spermicide (single barrier).  
D. Double Barrier Methods That May be Used Alone 
A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double-barrier).  
E. SEXUAL ABSTINENCE 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the 
patient.  
UNACCEPTABLE CONTRACEPTIVE METHODS 
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational am enorrhoea method (LAM) are not acceptable methods of contraception. 
Collection of Pregnancy Information:  
Male Patients with Partners Who Become Pregnant 
The Investigator will attempt to collect pregnancy information on any male patientâ€™s female 
partner who becomes pregnant while the male patient is in this st udy, or if they become pregnant 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524874] pregnancy information on the appropriate form and submit it to the 
sponsor within 24 hours of learning of the partne râ€™s pregnancy. The female  partner will also be 
followed to determine the outcome of the pregnanc y. Information on the status of the mother and 
child will be forwarded to the sponsor. Genera lly, the follow-up will be no longer than 6 to 8 
weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of  anomalies) or indicati on for the procedure.  
Female Patients Who Become Pregnant 
Any female patient who becomes pregnant while partic ipating in the study will discontinue study 
drug.  
The Investigator will collect pregnancy information on any female patient who becomes 
pregnant while participating in this study, or if they become pregnant [ADDRESS_524875] 
dose of study drug. The initial information will be recorded on the appropriate form and 
submitted to the sponsor within 24 hours of  learning of a patient's pregnancy.  
The patient will be followed to determine the outcome of the pregnancy. The Investigator will collect follow-up information on the patient and the neonate and the information will be forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks 
beyond the estimated delivery  date. Any termination of pregnancy will be reported, regardless of 
fetal status (presence or absence of anomalies) or indication for the procedure. 
While pregnancy itself is not cons idered to be an AE or SAE,  any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  A spontaneous abortion (occurring at < 22 weeks ge stational age) or still birth (occurring at > 
22 weeks gestational age) is always considered to be an SAE and will be reported as such.  Any post-study pregnancy related SAE considered reasonabl y related to the study drug by [CONTACT_416489] 8.5.5. While the Investigator 
is not obligated to actively seek this information in former study patients, he or she may learn of 
an SAE through spontaneous reporting.  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524876] 2021 
 
 
CONFIDENTIAL  Page 84 of 92  
 Appendix 8: COVID-19 Assessments 
At Screening:  
x SARS-CoV-2 testing to assess for active infection (e.g., molecular test such as 
polymerase chain reaction [PCR] or viral antigen serology) and past infection 
(Immunoglobulin G [IgG] and Immunoglobulin M [IgM] antibodies)  
x Testing at Screening may be omitted for patients who have completed a COVID-19 
vaccination series, with adequate documenta tion, at the Investigatorâ€™s discretion  
At Week 0, 6, and 12:  
x Testing for past infection via antibody testing (IgG and IgM) if prior IgG was negative  
x If Week 0 occurs within 2 weeks of Screeni ng, site may omit repeat SARS-CoV-2 testing 
at Investigatorâ€™s discretion 
x If IgM antibody test is positive, may reflex to  test for SARS-CoV-2 active infection at 
Investigatorâ€™s discretion 
x Testing at these timepoints may be omitted for patients who have completed a COVID-19 vaccination series, with adequate documenta tion, at the Investigatorâ€™s discretion  
Ad-hoc:  
x In the event of symptoms suggestive of CO VID-19, ad hoc testing (including molecular 
test such as PCR or viral antigen serology, and/or antibody testing), may be completed at 
Investigatorâ€™s discretion 
Sites may use local laboratory testing for COVID-[ADDRESS_524877] ion (e.g., molecular test such as PCR or viral 
antigen serology, or IgM antibody) require manageme nt per local public health guidelines, at the 
direction of the Investigator.  If technological changes result in changes to the assays implemented to assess for SARS-CoV-2, 
available central lab assays and testing mechanisms may change. 
The testing approach and schedule may be modified based on the evolving landscape of the 
pandemic or in response to lo cal public health requirements. In that event, regulatory 
requirements, IRB requirements, and local institutional guidelines will be followed, as necessary. 
 
 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524878] 2021 
 
 
CONFIDENTIAL  Page 85 of 92  
 Appendix 9: Abbreviations 
Abbreviation or 
special term Explanation 
AAT Alpha-[ADDRESS_524879] Aspartate transaminase 
AUC Area under the plasma concentration-time curve 
È•-hCG Human chorionic gonadotropin 
BMI  Body mass index 
BUN Biliary urea nitrogen 
C3M Type III collagen  
CAP Controlled attenuation parameter 
CBD Cannabidiol 
CCl 4 Carbon tetrachloride 
CDHFD Choline deficient high fat diet 
CFR Code of Federal Regulations 
CIOMS Council for International Organizations of Medical Sciences 
CK-18 Cytokeratin-18  
Cmax Maximum observed plasma concentration 
CNS Central nervous system 
CPK Creatinine phosphokinase 
CONSORT Consolidated Standards of Reporting Trials 
COVID-19 Coronavirus disease 2019  
CRF Case report form 
CSR Clinical study report 
CTCAE Common Terminology Criteria for Adverse Events 
cT1 Corrected T1  CV 
Coefficient of variation 
CYP Cytochrome P450 
DBL Database lock eCRF Electronic case report form 
eGFR Estimated glomerular filtration rate 
ECG Electrocardiogram EEG Electroencephalogram 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524880] 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524881] level 
PCR Polymerase chain reaction 
PD Pharmacodynamic(s)  
PI[INVESTIGATOR_416455] N-terminal propeptide  
PK Pharmacokinetic(s) 
po Per os (oral) 
PP Per protocol 
PPV Positive predictive value 
PRO-C3 Pro-peptide of type III collagen  
PT Prothrombin time 
PTZ Pentylenetetrazole  
QD Once daily 
RBC Red blood cell 
RNA Ribonucleic acid 
SAD Single ascending dose 
SAE Serious adverse event 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524882] 2021 
 
 
CONFIDENTIAL  Page 88 of 92  
 Abbreviation or 
special term Explanation 
SAP Statistical analysis plan 
SARS-COV-2 Severe Acute Respi[INVESTIGATOR_7531] 2 
SCr Standardized serum creatinine 
SSAO Semicarbazide-sensitive amine oxidase  
S[LOCATION_003]R Suspected unexpected serious adverse reactions 
TEAE Treatment emergent adverse event 
TERN-201 An investigational selective VAP-1/SSAO inhibitor; a.k.a., LSN3415221 
(LSN3379274Â·TsOH), LSN3394258 (LSN3379274Â·2HCl) and LSN3379274 
(free base)) 
THC Tetrahydrocannibinol 
TIMP-1 Tissue inhibitor of metalloproteinases-1  
TRN-001021 O-demethylation metabolite of TERN-201 
TRN-001744 O-dealkylation metabolite of TERN-201 
UACR Urine albumin:creatinine 
ULN Upper limit of normal  
UPCR Urine protein: creatinine 
US [LOCATION_002]  
VAP-1 Vascular Adhesion Protein-1 
VCAM-1 Vascular cell adhesion molecule-1 
VLDL Very low-density lipoprotein 
WBC White blood cell 
WOCBP Women of childbearing potential 
 
  
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524883] 2021 
 
 
CONFIDENTIAL  Page 89 of 92  
 Appendix 10: Investigator Signature [CONTACT_3490] 
A Multi-Center, Randomized, D ouble-Blind, Dose-Ranging, Pl acebo-Controlled, Proof of 
Concept, Adaptive, Phase 1b Clinical Study to  Evaluate the Safety, Pharmacokinetics, 
Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Pa tients with Presumed 
Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) 
Protocol Number:   TERN201-1007 
Protocol Version/Date:  Amendment 3; [ADDRESS_524884] 
the described study in compliance with all stipulations of the protocol, regulations and ICH E6 
Guideline for Good Clinical Practice (GCP). I will provide all st udy personnel under my 
supervision copi[INVESTIGATOR_416456], Inc. I will 
discuss this material with them to ensure that  they are fully informed about the study drug and 
the study. 
____________________________________ 
Principal Investigator [CONTACT_5627] (Printed)   ____________________________________ Signature   
____________________________________ Date   
 
 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524885] 2021 
 
 
CONFIDENTIAL  Page 90 of 92  
 Appendix 11: Protocol Amendment History 
This document (dated [ADDRESS_524886] 2021) is Amendm ent 3. The document history is below. The 
Summary of Changes for each amendment lis ted below will be pr ovided separately.  
DOCUMENT HISTORY 
Document Date 
Amendment [ADDRESS_524887] 2021 
Amendment 2 21 June 2021 
Amendment 1 20 April 2021 
Original 18 December 2020 
 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524888] 2021 
 
 
CONFIDENTIAL  Page 91 of 92  
 Appendix 12: References 
Andronescu CI, Purcarea MR, Ba bes PA. Nonalcoholic  fatty liver disease: epi[INVESTIGATOR_623], 
pathogenesis and therapeutic implications. J Med Life. 2018;11(1):20â€“23. 
Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-
invasive diagnosis of liver dis ease. J Hepatol. 2014;60(1):69-77.  
Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by 
[CONTACT_9268]-PDFF as an endpoint in NASH trials. Hepatol ogy. 2018;68(2):763-772.  
Chalasani N, Younossi Z,2 Lavine JE, Charlton M,  Cusi K, Rinella M, Harrison SA, Brunt EM, 
and Sanyal AJ. The Diagnosis and Management of N onalcoholic Fatty Liver Disease: Practice 
Guidance from the American Association for the Study of Liver Diseases. Hepatol. 2018;67:328-
57. 
Dennis A, Kelly MD, Fernandes C et al. Correla tions between MRI biomarkers PDFF and cT1 
with histopathological feat ures of non-alcoholic steatohepatitis. Front Endocrinol. 
2021:11:575843.  
de Zeeuw D. Efficacy of a novel inhibitor of va scular adhesion protein-1 in reducing albuminuria 
in patients with diabetic kidney disease (ALBUM):  a randomised, placebo-co ntrolled, phase 2 trial. 
Lancet Diabetes Endocrinol 2018; 6: 925â€“33. 
Eddowes PJ et al. Accuracy of FibroScanÂ® controlled attenuation parameter and liver stiffness 
measurement in assessing steatosis  and fibrosis in patients with nonalcoholic fatty liver disease. 
Gastroenterol. 2019;156:1717â€“30. 
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, St al P, Kechagias S et al. Fibrosis Stage is the 
Strongest Predictor for Disease-sp ecific Mortality in NAFLD After up to 33 years of Follow-up. 
Hepatology. 2015;61:1547-54. Harrison SA et al. Selonsertib for patients with br idging fibrosis or compensated cirrhosis due to 
NASH: Results from randomized phase III STELLAR trials J. Hepatol. 2020; 73:26-39. 
Mojtahed A et al. Reference range of liver corrected  T1 values in a population at low risk for fatty 
liver diseaseâ€”a [LOCATION_006] Biobank sub-study, with an a ppendix of interesting cases. Abdom Radiol. 
2019;44:72â€“84. 
National Heart, Lung, and Blood Institute. The Pr actical Guide: Identification, Evaluation, and 
Treatment of Overweight and Obesity in Adults. US Department of Hea lth and Human Services, 
Public Health Service, Nationa l Institutes of Health, Nationa l Heart Lung and Blood Institute, 
Bethesda, MD, October 2000. Accessed on 29 January 220 at 
https://www.nhlbi.nih.gov/files/ docs/guidelines/prctgd_c.pdf. 
Salmi M. Vascular Adhesion Pr otein-1: A Cell Surface Amine Oxidase in Translation. 
Antioxidants Redox Signaling. 2019a;30:314-32. 
Protocol TERN201-1007 
Terns, Inc.  Version: Amendment 3 
Version Date: [ADDRESS_524889] 2021 
 
 
CONFIDENTIAL  Page 92 of 92  
 Schilter HC, Collison A, Russo RC, et al. Effects of an anti-inflammatory VAP-1/SSAO inhibitor, 
PXS-4728A, on pulmonary neutrophil migration. Respir Res. 2015;16:42. 
Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion protein 
1 reveals a novel multifunctiona l adhesion molecule. J Exp Med. 1998;188:17-27. Szczepaniak 
LS. Magnetic resonance spectroscopy to measure he patic triglyceride content: prevalence of 
hepatic steatosis in the ge neral population. Am J Physio l Endocrinol Metab 2005;288:E462â€“
E468. 
Tang A et al. Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat 
Fraction to Assess Hepatic Steatosis. Radiology 2013; 267:422â€“431. 
Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, Tomlinson JW, Hubscher 
SG, Reynolds GM, Aalto K, Anstee QM, Jalkanen S, Salmi M, Smith DJ, Day CP, Adams DH. Vascular adhesion protein-[ADDRESS_524890]. 
2015;125(2):501-20. 
 
  